← 產業報告目錄

Patient Engagement Solutions Market by Therapy (CVD, Diabetes, Obesity, Fitness), Functionality (Telehealth, E-Prescribing, Scheduling, Billing), End User (Hospital, Payer, Patient), Unmet Need, Investment, Market Share, and Trends - Global Forecast to 2030

出版商 MarketsandMarkets產業別 Healthcare & Life Sciences出版日期 2026-01-16頁數 426報告編號 MNM-8b37a37626

授權報價

Single User Licence$4,950 USD
Multi User Licence$6,650 USD
Corporate User Licence$8,150 USD
Global User Licence$10,000 USD
洽詢購買 申請 Sample

報告摘要

The patient engagement solutions market is projected to reach USD 51.69 billion by 2030 from USD 29.33 billion in 2025, at a CAGR of 12.0% during the forecast period. Factors such as the rising use of digital solutions that allow real-time communication, personalized interaction, and easy interfacing. Others may include advancements such as cloud solutions, mobile solutions, and analytics. High investment requirements for healthcare infrastructure and a lack of skilled IT professionals in the healthcare sector are anticipated to impede the growth of this market . “Services segment is expected to grow at the highest rate during the forecast period.” By components, the patient engagement solutions market is divided into software, hardware, and services. The services segment is expected to grow at the fastest rate as healthcare organizations increasingly seek support for implementation, customization, integration with EHRs, change management, training, and ongoing optimization of engagement technologies. These professional and managed services help providers and payers maximize the value of engagement platforms, adapt to evolving clinical workflows, and ensure seamless deployment across complex healthcare environments . “The on-premise segment is anticipated to dominate the Patient Engagement Solutions market in 2024” By delivery modes, the patient engagement solutions market is categorized into on-premise and cloud-based/web-based modes. In 2024, the on-premise segment is expected to dominate because many healthcare organizations, especially large hospitals and health systems, prefer to maintain direct control over sensitive patient data and core clinical systems. On-premise deployments also align with established IT infrastructures, existing EHR environments, and stringent security and compliance requirements, making them a dominant choice for organizations prioritizing data governance and internal integration . “Health management segment accounted for the largest share of the global patient engagement solutions market, by applications” By application, the patient engagement solutions market is divided into health management, home health management, social and behavioral management, and financial health management. In 2024, the health management applications segment accounts held the largest share of the global patient engagement solutions market. It encompasses comprehensive care coordination, chronic disease management, and population health initiatives that rely heavily on engagement tools to maintain continuous patient communication. These solutions help providers and payers monitor patient outcomes, close care gaps, and support preventive care, making health management the dominant application driving adoption of engagement platforms . “Providers' segment accounted for the largest share of the global patient engagement solutions market, by end user in 2024.” By end users, the patient engagement solutions market is divided into providers, payers, patients, and other end users. The providers are further bifurcated into hospitals and healthcare system, ambulatory care centers, home healthcare, and other providers. Moreover the payers is further divided into private and public. By end users, the providers' segment accounted for the largest share of the global patient engagement solutions market in 2024. The large share of this segment is due to increasing implementation of patient engagement solutions to curtail mounting healthcare costs, offer value-based care, and expand financial outcomes are factors that are driving the growth of this segment. “North America to dominate the patient engagement solutions market In 2024, North America dominated the global patient engagement solutions market by region. Factors such as favorable government initiatives and regulations, the imperative to reduce healthcare costs, the increasing prevalence of chronic diseases, and the presence of key market players contribute significantly to the growth of the patient engagement solutions market in North America. Strong regulatory frameworks promoting patient access, data interoperability, and value-based care, along with the presence of leading healthcare IT vendors and high healthcare spending, continue to drive market leadership in the region . Breakdown of supply-side primary interviews, by company type, designation, and region: • By Company Type: Tier 1 (45%), Tier 2 (30%), and Tier 3 (25%) • By Designation: C-level (44%), Director-level (35%), and Others (21%) • By Region: North America (46%), Europe (26%), Asia Pacific (18%), Latin America (7%), and Middle East & Africa (10%) McKesson Corporation (US), Veradigm LLC (US), Oracle (US), athenahealth (US), Health Catalyst (US), GetWellNetwork, Inc. (US), Lincata, Inc. (US), Cognizant (US), TruBridge (US), Oneview Healthcare (Ireland), AdvancedMD, Inc. (US), Epic Systems Corporation (US), Harris Healthcare (US), Medical Information Technology, Inc. (US), Tebra Technologies, Inc. (US), Televox (US), Medhost (US), Nuance Communications, Inc. (US) (Microsoft), Solutionreach, Inc. (US), Experian Information Solutions, Inc. (US). These players are increasingly focusing on new product launches and partnerships to expand their product offerings in the patient engagement solutions market. Research Coverage • The report studies the Patient Engagement Solutions market based on component, delivery mode, therapeutic area, application, functionality, end user, and region. • The report analyzes factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth. • The report evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. • The report studies micro-markets with respect to their growth trends, prospects, and contributions to the total patient engagement solutions market. • The report forecasts the revenue of market segments with respect to five major regions. Reasons to Buy the Report • This report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share of the market. Firms purchasing the report could use one or a combination of the below-mentioned strategies to strengthen their positions in the market. • Analysis of key drivers (implementation of government regulations and initiatives to promote patient centric care, increasing adoption of patient engagement solutions, rising number of collaborations and partnerships between stakeholders, increasing utilisation of mobile health apps, rising geriatric population and subsequent increase in prevalence of chronic diseases), restraints (large investment requirement for healthcare infrastructure, protection of patient information, inadequate interoperability across healthcare providers and shortage of skilled IT professionals in the healthcare industry ), opportunities (growth opportunities in emerging markets, wearable health technology, cloud computing solutions), and challenges (high deployment cost of healthcare IT systems, low levels of healthcare literacy) impacting the growth of the patient engagement solutions market. • Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the patient engagement solutions market. • Market Development: Comprehensive information on the lucrative emerging markets, component, delivery mode, therapeutic area, application, functionality, end user, and region • Market Diversification: Exhaustive information about the product portfolios, growing geographies, recent developments, and investments in the patient engagement solutions market • Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, company evaluation quadrant, and capabilities of leading players in the global patient engagement market.
目錄 Table of Contents
1 INTRODUCTION 41 1.1 STUDY OBJECTIVES 41 1.2 MARKET DEFINITION 41 1.3 STUDY SCOPE 42 1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE 42 1.3.2 INCLUSIONS & EXCLUSIONS 43 1.3.3 YEARS CONSIDERED 44 1.3.4 CURRENCY CONSIDERED 44 1.4 STAKEHOLDERS 45 1.5 SUMMARY OF CHANGES 45 2 EXECUTIVE SUMMARY 47 2.1 KEY INSIGHTS & MARKET HIGHLIGHTS 47 2.2 KEY MARKET PARTICIPANTS: SHARE INSIGHTS AND STRATEGIC DEVELOPMENTS 48 2.3 DISRUPTIVE TRENDS SHAPING MARKET 49 2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS 50 2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST 51 3 PREMIUM INSIGHTS 52 3.1 PATIENT ENGAGEMENT SOLUTIONS MARKET OVERVIEW 52 3.2 PATIENT ENGAGEMENT SOLUTIONS MARKET, BY DELIVERY MODE AND REGION 53 3.3 PATIENT ENGAGEMENT SOLUTIONS MARKET: GEOGRAPHIC SNAPSHOT 54 4 MARKET OVERVIEW 55 4.1 INTRODUCTION 55 4.2 MARKET DYNAMICS 55 4.2.1 DRIVERS 56 4.2.1.1 Increasing adoption of telehealth and remote care 56 4.2.1.2 Increasing smartphone use and digital comfort 56 4.2.1.3 Implementation of government regulations and initiatives to promote patient-centric care 57 4.2.1.4 Growing prevalence of chronic diseases and rising demand for long-term patient involvement 57 4.2.2 RESTRAINTS 58 4.2.2.1 Data privacy and cybersecurity concerns 58 4.2.2.2 Inadequate interoperability across healthcare providers 58 4.2.2.3 Shortage of skilled IT professionals in healthcare industry 59 4.2.3 OPPORTUNITIES 59 4.2.3.1 Expansion of remote and home-based care models 59 4.2.3.2 AI-driven personalization in patient engagement solutions 60 4.2.3.3 Integration with wearables and personalized health tech 60 4.2.4 CHALLENGES 60 4.2.4.1 Low patient adoption and engagement over time 60 4.2.4.2 Fragmented data and siloed digital tools 61 4.3 UNMET NEEDS & WHITE SPACES 61 4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES 61 4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS 62 5 INDUSTRY TRENDS 63 5.1 PORTER’S FIVE FORCES ANALYSIS 63 5.1.1 BARGAINING POWER OF SUPPLIERS 64 5.1.2 BARGAINING POWER OF BUYERS 64 5.1.3 THREAT OF SUBSTITUTES 64 5.1.4 THREAT OF NEW ENTRANTS 64 5.1.5 INTENSITY OF COMPETITIVE RIVALRY 64 5.2 MACROECONOMICS OUTLOOK 65 5.2.1 INTRODUCTION 65 5.2.2 GDP TRENDS AND FORECAST 65 5.2.3 TRENDS IN GLOBAL HEALTHCARE IT INDUSTRY 65 5.3 VALUE CHAIN ANALYSIS 65 5.4 ECOSYSTEM ANALYSIS 67 5.4.1 ROLE IN ECOSYSTEM 68 5.5 PRICING ANALYSIS 69 5.5.1 INDICATIVE PRICE FOR PATIENT ENGAGEMENT SOLUTIONS, BY COMPONENT, 2025 69 5.5.2 INDICATIVE PRICE FOR PATIENT ENGAGEMENT SOLUTIONS, BY REGION, 2025 70 5.6 TRADE ANALYSIS 70 5.6.1 IMPORT SCENARIO FOR HS CODE 8528, 2021–2024 71 5.6.2 IMPORT SCENARIO FOR HS CODE 8471, 2021–2024 71 5.6.3 EXPORT SCENARIO FOR HS CODE 8528, 2021–2024 72 5.6.4 EXPORT SCENARIO FOR HS CODE 8471, 2021–2024 73 5.7 KEY CONFERENCES AND EVENTS, 2026–2027 74 5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS 75 5.9 INVESTMENT & FUNDING SCENARIO 75 5.10 CASE STUDY ANALYSIS 76 5.10.1 ACHIEVING USD 15 MILLION IN SAVINGS BY REDUCING READMISSIONS WITH POST-DISCHARGE FOLLOW-UP 76 5.10.2 BUILD TRUST THROUGH PATIENT ENGAGEMENT TECHNOLOGY: CHILDREN’S HOSPITAL CASE STUDY 77 5.10.3 IMPROVING PATIENT ENGAGEMENT AT SPARTA COMMUNITY HOSPITAL WITH TRUBRIDGE PATIENT CONNECT 77   5.11 IMPACT OF 2025 US TARIFF ON PATIENT ENGAGEMENT SOLUTIONS MARKET 78 5.11.1 KEY TARIFF RATES 78 5.11.2 PRICE IMPACT ANALYSIS 79 5.11.3 IMPACT ON COUNTRY/REGION 80 5.11.3.1 US 80 5.11.3.2 Europe 80 5.11.3.3 Asia Pacific 80 5.11.4 IMPACT ON END-USE INDUSTRIES 81 5.11.4.1 Hospitals and healthcare systems 81 5.11.4.2 ASCs, ACCs, and other outpatient settings 81 5.11.4.3 Home healthcare providers 81 5.11.4.4 Private payers 81 5.11.4.5 Public payers 81 5.11.4.6 Other end users 81 6 STRATEGIC DISRUPTION THROUGH TECHNOLOGY, PATENTS, DIGITAL, AND AI ADOPTIONS 82 6.1 KEY EMERGING TECHNOLOGIES 82 6.1.1 CLOUD COMPUTING 82 6.1.2 API & EHR INTEGRATION TECHNOLOGIES 82 6.1.3 DATA ANALYTICS 82 6.2 COMPLEMENTARY TECHNOLOGIES 83 6.2.1 ARTIFICIAL INTELLIGENCE (AI) AND MACHINE LEARNING (ML) 83 6.2.2 CONVERSATIONAL AI/CHATBOTS 83 6.2.3 BEHAVIORAL ANALYTICS AND PERSONALIZATION ENGINES 84 6.3 ADJACENT TECHNOLOGIES 84 6.3.1 CYBERSECURITY AND DATA ENCRYPTION 84 6.3.2 BLOCKCHAIN 85 6.3.3 BIG DATA AND ADVANCED ANALYTICS 85 6.4 TECHNOLOGY/PRODUCT ROADMAP 85 6.5 PATENT ANALYSIS 86 6.5.1 PATENT PUBLICATION TRENDS FOR PATIENT ENGAGEMENT SOLUTION 86 6.5.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS 87 6.5.3 LIST OF PATENTS/PATENT APPLICATIONS 88 6.6 FUTURE APPLICATIONS 89 6.6.1 AI-DRIVEN PREDICTIVE ENGAGEMENT 89 6.6.2 CONTINUOUS REMOTE CARE AND HOSPITAL-AT-HOME ENABLEMENT 89 6.6.3 PERSONALIZED DIGITAL THERAPEUTICS AND BEHAVIORAL COACHING 89 6.6.4 CLOSED-LOOP CARE COORDINATION AND VALUE-BASED PERFORMANCE OPTIMIZATION 90 6.6.5 DECENTRALIZED CLINICAL TRIALS AND REAL-WORLD EVIDENCE GENERATION 90   6.7 IMPACT OF AI/GEN AI ON PATIENT ENGAGEMENT SOLUTIONS MARKET 90 6.7.1 INTRODUCTION 90 6.7.2 MARKET POTENTIAL OF AI/GEN AI IN PATIENT ENGAGEMENT SOLUTIONS MARKET 91 6.7.3 CASE STUDIES RELATED TO AI/GEN AI IMPLEMENTATION 92 6.7.3.1 AI-driven conversational AI for pre/post-op engagement 92 6.7.4 IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS 93 6.7.4.1 Patient communication & virtual care platforms 93 6.7.4.2 Remote patient monitoring & digital therapeutics 93 6.7.4.3 Population health & health equity programs 94 6.7.5 USER READINESS AND IMPACT ASSESSMENT 94 6.7.5.1 User readiness 94 6.7.5.1.1 User A: Hospitals & clinics 94 6.7.5.1.2 User B: Healthcare providers, employers, and forensic agencies 94 6.7.5.2 Impact assessment 95 6.7.5.2.1 User A: Clinical, reference, and toxicology laboratories 95 6.7.5.2.2 User B: Healthcare providers, employers, and forensic agencies 95 7 REGULATORY LANDSCAPE 96 7.1 REGIONAL REGULATIONS & COMPLIANCE 96 7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 96 7.1.2 REGULATORY FRAMEWORK 101 7.1.2.1 North America 101 7.1.2.2 Europe 102 7.1.2.3 Asia Pacific 102 7.1.2.4 Latin America 103 7.1.2.5 Middle East & Africa 104 7.1.3 INDUSTRY STANDARDS 104 8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 105 8.1 INTRODUCTION 105 8.2 DECISION-MAKING PROCESS 105 8.3 BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA 105 8.3.1 KEY STAKEHOLDERS IN BUYING PROCESS 106 8.3.2 BUYING CRITERIA 106 8.4 ADOPTION BARRIERS & INTERNAL CHALLENGES 107 8.5 UNMET NEEDS/END-USER EXPECTATIONS 108 8.5.1 UNMET NEEDS 108 8.5.2 END-USER EXPECTATIONS 109 8.6 MARKET PROFITIBILITY 110 9 PATIENT ENGAGEMENT SOLUTIONS MARKET, BY COMPONENT 111 9.1 INTRODUCTION 112 9.2 HARDWARE 112 9.2.1 IN-ROOM TELEVISIONS 113 9.2.1.1 Rising patient demand for real-time health transparency and smart room modernization initiatives to drive market 113 9.2.2 INTEGRATED BEDSIDE TERMINALS/ASSISTED DEVICES 114 9.2.2.1 Hospitals to increasingly adopt bedside terminals to address workforce shortages and reduce nursing workload 114 9.2.3 TABLETS 115 9.2.3.1 Strong ROI profile, lower upfront investment, and rapid rollout capability to propel market growth 115 9.3 SOFTWARE 116 9.3.1 PRE-CARE ENGAGEMENT 117 9.3.1.1 Increasing adoption of consumer-centric access models to aid segment growth 117 9.3.2 POINT-OF-CARE ENGAGEMENT 118 9.3.2.1 Exponential growth in healthcare data and rising information complexity to augment segment growth 118 9.3.3 POST-CARE ENGAGEMENT 119 9.3.3.1 Shift toward value-based care and reimbursement models for readmission rates to drive segment growth 119 9.4 SERVICES 120 9.4.1 IMPLEMENTATION & INTEGRATION SERVICES 122 9.4.1.1 Need for expertise to operationalize sophisticated patient engagement ecosystems to fuel market growth 122 9.4.2 TRAINING & EDUCATION SERVICES 123 9.4.2.1 Need to eradicate measurable staff usability challenges and patient digital access gaps to drive segment 123 9.4.3 SUPPORT & MAINTENANCE SERVICES 124 9.4.3.1 Dependency on patient portals, telehealth systems, and integrated EHR infrastructures to aid market growth 124 9.4.4 CONSULTING SERVICES 125 9.4.4.1 Shift from volume-based to value-based care models to drive consulting services market 125 10 PATIENT ENGAGEMENT SOLUTIONS MARKET, BY DELIVERY MODE 126 10.1 INTRODUCTION 127 10.2 ON-PREMISES 127 10.2.1 ON-PREMISES ADOPTION TO ACCELERATE AMID SECURITY, REGULATORY, AND INTEGRATION PRIORITIES 127 10.3 CLOUD-BASED 128 10.3.1 CLOUD-BASED PATIENT ENGAGEMENT TO PROPEL SCALABLE, SECURE, AND INTEROPERABLE CARE 128   11 PATIENT ENGAGEMENT SOLUTIONS MARKET, BY APPLICATION 130 11.1 INTRODUCTION 131 11.2 CLINICAL CARE 131 11.2.1 VALUE-BASED CARE MODELS AND TELEHEALTH EXPANSION TO PROPEL CLINICAL CARE SEGMENT 131 11.3 CARE COORDINATION & COMMUNICATION 132 11.3.1 FRAGMENTED CARE PATHWAYS AND INTEROPERABILITY MANDATES TO ACCELERATE MARKET GROWTH 132 11.4 HOME & REMOTE CARE 133 11.4.1 HOSPITAL-AT-HOME EXPANSION, READMISSION PENALTIES, AND RPM REIMBURSEMENT TO FUEL SEGMENT GROWTH 133 11.5 POPULATION HEALTH & BEHAVIORAL ENGAGEMENT 135 11.5.1 VALUE-BASED CARE MANDATES, RISK STRATIFICATION, AND BEHAVIORAL HEALTH INTEGRATION TO PROPEL SEGMENT GROWTH 135 11.6 FINANCIAL ENGAGEMENT 136 11.6.1 RISING OUT-OF-POCKET COSTS, CONSUMERISM, AND REVENUE PRESSURE TO DRIVE FINANCIAL ENGAGEMENT ADOPTION 136 11.7 OTHER APPLICATIONS 137 12 PATIENT ENGAGEMENT SOLUTIONS MARKET, BY THERAPEUTIC AREA 139 12.1 INTRODUCTION 140 12.2 CHRONIC DISEASES 140 12.2.1 CARDIOVASCULAR DISEASES 142 12.2.1.1 Need for continuous monitoring and preventive engagement through digital health platforms to drive market 142 12.2.2 DIABETES 143 12.2.2.1 Continuous glucose monitoring, behavioral adherence, and data-driven self-management through digital engagement to drive market 143 12.2.3 OBESITY 144 12.2.3.1 Preventive engagement, behavioral modification, and long-term risk reduction through digital health platforms to drive market 144 12.2.4 RESPIRATORY DISORDERS 145 12.2.4.1 Advancing continuous symptom monitoring and preventive care through digital engagement platforms to fuel market growth 145 12.2.5 ONCOLOGY 146 12.2.5.1 Longitudinal care coordination, symptom monitoring, and survivorship engagement to boost market 146 12.2.6 OTHER CHRONIC DISEASES 146 12.3 WOMEN'S HEALTH 147 12.3.1 PREVENTIVE SCREENING, REPRODUCTIVE CARE COORDINATION, AND LIFECYCLE ENGAGEMENT TO AID MARKET GROWTH 147 12.4 BEHAVIORAL & MENTAL HEALTH 148 12.4.1 INCREASING GLOBAL PREVALENCE OF DEPRESSION, ANXIETY, SUBSTANCE USE DISORDERS TO AID MARKET GROWTH 148 12.5 OTHER THERAPEUTIC AREAS 149 13 PATIENT ENGAGEMENT SOLUTIONS MARKET, BY FUNCTIONALITY 151 13.1 INTRODUCTION 152 13.2 PATIENT/CLIENT SCHEDULING 152 13.2.1 DIGITAL-FIRST, MOBILE-DRIVEN SCHEDULING TO REDUCE NO-SHOWS AND STRENGTHEN ACCESS PERFORMANCE 152 13.3 TELEHEALTH 153 13.3.1 TELEHEALTH TO DRIVE QUALITY IMPROVEMENT AND HYBRID CARE DELIVERY GROWTH 153 13.4 E-PRESCRIBING 154 13.4.1 E-PRESCRIBING TO STRENGTHEN MEDICATION SAFETY REGULATORY COMPLIANCE 154 13.5 DOCUMENT MANAGEMENT 155 13.5.1 DIGITAL RECORD ACCESS TO DRIVE DOCUMENT MANAGEMENT IN CORE PATIENT ENGAGEMENT INFRASTRUCTURE 155 13.6 BILLING & PAYMENTS 157 13.6.1 RISING PATIENT FINANCIAL RESPONSIBILITY AND GROWING DEMAND FOR DIGITAL TRANSPARENCY TO DRIVE MARKET 157 13.7 PATIENT EDUCATION 158 13.7.1 SELF-DIRECTED HEALTH RESEARCH AND DIGITAL LITERACY GAPS TO RISE DEMAND FOR INTEGRATED PATIENT EDUCATION TOOLS 158 13.8 OTHER FUNCTIONALITIES 159 14 PATIENT ENGAGEMENT SOLUTIONS MARKET, BY END USER 160 14.1 INTRODUCTION 161 14.2 PROVIDERS 161 14.2.1 HOSPITALS & HEALTHCARE SYSTEMS 162 14.2.1.1 Healthcare systems to drive patient experience and operational efficiency through integrated patient engagement solutions 162 14.2.2 ASCS, ACCS, AND OTHER OUTPATIENT SETTINGS 163 14.2.2.1 Need for optimizing patient access and engagement in outpatient care settings to propel segment growth 163 14.2.3 HOME HEALTHCARE PROVIDERS 164 14.2.3.1 Home healthcare provides to enhance patient engagement and remote care delivery in home settings 164 14.2.4 OTHER PROVIDERS 164 14.3 PAYERS 165 14.3.1 PRIVATE PAYERS 166 14.3.1.1 Private payers to enhance member experience and cost efficiency through digital-first engagement strategies 166 14.3.2 PUBLIC PAYERS 167 14.3.2.1 Public payers to strengthen population health management through inclusive and scalable digital engagement 167 14.4 OTHER END USERS 168   15 PATIENT ENGAGEMENT SOLUTIONS MARKET, BY REGION 169 15.1 INTRODUCTION 170 15.2 NORTH AMERICA 170 15.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 171 15.2.2 US 178 15.2.2.1 Value-based care reforms and long-term care management need to accelerate market growth 178 15.2.3 CANADA 183 15.2.3.1 Government policies to strengthen digital health infrastructure and interoperability 183 15.3 EUROPE 188 15.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 188 15.3.2 GERMANY 194 15.3.2.1 Nationwide ePA rollout and digital therapeutics leadership to propel market growth 194 15.3.3 FRANCE 200 15.3.3.1 Near-universal digital health record adoption and strategic investment to aid market growth 200 15.3.4 UK 205 15.3.4.1 NHS app scale-up and virtual care expansion to boost market growth 205 15.3.5 ITALY 210 15.3.5.1 Rising digital health investment and growing focus on national telemedicine infrastructure to fuel market growth 210 15.3.6 SPAIN 215 15.3.6.1 Rising telemedicine expansion and growing mHealth adoption to strengthen market 215 15.3.7 REST OF EUROPE 220 15.4 ASIA PACIFIC 226 15.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 226 15.4.2 CHINA 233 15.4.2.1 High digital health adoption and internet hospital expansion to accelerate market growth 233 15.4.3 JAPAN 238 15.4.3.1 Healthcare digitalization to accelerate patient engagement in Japan 238 15.4.4 INDIA 243 15.4.4.1 Digital public health infrastructure and mobile penetration to augment market growth 243 15.4.5 SOUTH KOREA 248 15.4.5.1 National digital integration and rapid population aging to aid market growth 248 15.4.6 AUSTRALIA 253 15.4.6.1 Near-universal digital records and embedded telehealth adoption to fuel market growth 253 15.4.7 REST OF ASIA PACIFIC 258   15.5 LATIN AMERICA 264 15.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 264 15.5.2 BRAZIL 270 15.5.2.1 Government-led telehealth scale and institutionalized patient participation to propel digital engagement 270 15.5.3 MEXICO 275 15.5.3.1 Structural health system gaps to spur digital patient engagement adoption 275 15.5.4 REST OF LATIN AMERICA 280 15.6 MIDDLE EAST & AFRICA 285 15.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 285 15.6.2 GCC COUNTRIES 290 15.6.2.1 High NCD burden and government-owned digital platforms to augment patient engagement 290 15.6.2.2 Kingdom of Saudi Arabia 295 15.6.2.2.1 Government-led digital health innovations to accelerate patient engagement 295 15.6.2.3 UAE 300 15.6.2.3.1 Progressive digital health innovations to strengthen UAE patient engagement solutions market 300 15.6.2.4 Rest of GCC countries 304 15.6.3 SOUTH AFRICA 309 15.6.3.1 Massive telemedicine adoption and innovative digital platforms to aid market growth 309 15.6.4 REST OF MIDDLE EAST & AFRICA 314 16 COMPETITIVE LANDSCAPE 320 16.1 INTRODUCTION 320 16.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 320 16.2.1 OVERVIEW OF KEY STRATEGIES ADOPTED BY KEY PLAYERS IN PATIENT ENGAGEMENT SOLUTIONS MARKET 320 16.3 REVENUE ANALYSIS, 2020–2024 322 16.4 MARKET SHARE ANALYSIS, 2024 323 16.5 BRAND COMPARISON 325 16.6 COMPANY VALUATION & FINANCIAL METRICS 326 16.6.1 FINANCIAL METRICS 326 16.6.2 COMPANY VALUATION 326 16.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 327 16.7.1 STARS 327 16.7.2 EMERGING LEADERS 327 16.7.3 PERVASIVE PLAYERS 327 16.7.4 PARTICIPANTS 327   16.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 329 16.7.5.1 Company footprint 329 16.7.5.2 Region footprint 330 16.7.5.3 Component footprint 331 16.7.5.4 Application footprint 332 16.7.5.5 End-user footprint 333 16.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 333 16.8.1 PROGRESSIVE COMPANIES 333 16.8.2 RESPONSIVE COMPANIES 334 16.8.3 DYNAMIC COMPANIES 334 16.8.4 STARTING BLOCKS 334 16.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024 335 16.8.5.1 Detailed list of key startups/SMEs 335 16.8.5.2 Competitive benchmarking of startups/SMEs 335 16.9 COMPETITIVE SCENARIO 336 16.9.1 PRODUCT LAUNCHES & ENHANCEMENTS 336 16.9.2 DEALS 337 16.9.3 EXPANSIONS 338 16.9.4 OTHER DEVELOPMENTS 338 17 COMPANY PROFILES 339 17.1 KEY PLAYERS 339 17.1.1 MCKESSON CORPORATION 339 17.1.1.1 Business overview 339 17.1.1.2 Products offered 340 17.1.1.3 Recent developments 341 17.1.1.3.1 Deals 341 17.1.1.4 MnM view 341 17.1.1.4.1 Right to win 341 17.1.1.4.2 Strategic choices 342 17.1.1.4.3 Weaknesses & competitive threats 342 17.1.2 ORACLE 343 17.1.2.1 Business overview 343 17.1.2.2 Products offered 344 17.1.2.3 Recent developments 345 17.1.2.3.1 Product launches 345 17.1.2.3.2 Deals 345 17.1.2.4 MnM view 346 17.1.2.4.1 Right to win 346 17.1.2.4.2 Strategic choices 346 17.1.2.4.3 Weaknesses & competitive threats 346   17.1.3 MICROSOFT (NUANCE COMMUNICATIONS, INC.) 347 17.1.3.1 Business overview 347 17.1.3.2 Products offered 348 17.1.3.3 Recent developments 349 17.1.3.3.1 Product launches 349 17.1.3.3.2 Deals 349 17.1.3.4 MnM view 349 17.1.3.4.1 Right to win 349 17.1.3.4.2 Strategic choices 350 17.1.3.4.3 Weaknesses & competitive threats 350 17.1.4 TRUBRIDGE 351 17.1.4.1 Business overview 351 17.1.4.2 Products offered 352 17.1.4.3 Recent developments 353 17.1.4.3.1 Deals 353 17.1.4.4 MnM view 354 17.1.4.4.1 Right to win 354 17.1.4.4.2 Strategic choices 354 17.1.4.4.3 Weaknesses & competitive threats 354 17.1.5 HEALTH CATALYST 355 17.1.5.1 Business overview 355 17.1.5.2 Products offered 356 17.1.5.3 Recent developments 357 17.1.5.3.1 Deals 357 17.1.5.4 MnM view 357 17.1.5.4.1 Right to win 357 17.1.5.4.2 Strategic choices 357 17.1.5.4.3 Weaknesses & competitive threats 357 17.1.6 VERADIGM LLC 358 17.1.6.1 Business overview 358 17.1.6.2 Products offered 359 17.1.6.3 Recent developments 360 17.1.6.3.1 Product launches 360 17.1.6.3.2 Deals 360 17.1.7 ATHENAHEALTH 361 17.1.7.1 Business overview 361 17.1.7.2 Products offered 361 17.1.7.3 Recent developments 362 17.1.7.3.1 Product launches and enhancements 362 17.1.7.3.2 Deals 363 17.1.7.3.3 Other developments 363   17.1.8 GETWELLNETWORK, INC. 365 17.1.8.1 Business overview 365 17.1.8.2 Products offered 365 17.1.8.3 Recent developments 366 17.1.8.3.1 Product enhancements 366 17.1.8.3.2 Deals 367 17.1.9 LINCATA, INC. 368 17.1.9.1 Business overview 368 17.1.9.2 Products offered 368 17.1.10 COGNIZANT 370 17.1.10.1 Business overview 370 17.1.10.2 Products offered 371 17.1.10.3 Recent developments 372 17.1.10.3.1 Deals 372 17.1.11 ONEVIEW HEALTHCARE 373 17.1.11.1 Business overview 373 17.1.11.2 Products offered 374 17.1.11.3 Recent developments 375 17.1.11.3.1 Product launches and enhancements 375 17.1.11.3.2 Deals 376 17.1.11.3.3 Other developments 376 17.1.12 ADVANCEDMD, INC. 377 17.1.12.1 Business overview 377 17.1.12.2 Products offered 377 17.1.12.3 Recent developments 379 17.1.12.3.1 Product enhancements 379 17.1.12.3.2 Deals 380 17.1.13 EPIC SYSTEMS CORPORATION 381 17.1.13.1 Business overview 381 17.1.13.2 Products offered 381 17.1.13.3 Recent developments 382 17.1.13.3.1 Product enhancement 382 17.1.13.3.2 Deals 383 17.1.14 HARRIS HEALTHCARE 384 17.1.14.1 Business overview 384 17.1.14.2 Products offered 384 17.1.14.3 Recent developments 385 17.1.14.3.1 Deals 385   17.1.15 MEDICAL INFORMATION TECHNOLOGY, INC. 386 17.1.15.1 Business overview 386 17.1.15.2 Products offered 386 17.1.15.3 Recent developments 387 17.1.15.3.1 Deals 387 17.1.15.3.2 Other developments 387 17.1.16 TEBRA TECHNOLOGIES, INC. 388 17.1.16.1 Business overview 388 17.1.16.2 Products offered 388 17.1.16.3 Recent developments 389 17.1.16.3.1 Product enhancements 389 17.1.16.3.2 Deals 389 17.1.17 TELEVOX 390 17.1.17.1 Business overview 390 17.1.17.2 Products offered 390 17.1.17.3 Recent developments 391 17.1.17.3.1 Product launches 391 17.1.17.3.2 Deals 391 17.1.18 SOLUTIONREACH, INC. 392 17.1.18.1 Business overview 392 17.1.18.2 Products offered 392 17.1.18.3 Recent developments 393 17.1.18.3.1 Product launches and enhancements 393 17.1.19 EXPERIAN INFORMATION SOLUTIONS, INC. 394 17.1.19.1 Business overview 394 17.1.19.2 Products offered 395 17.1.20 ECLINICALWORKS 397 17.1.20.1 Business overview 397 17.1.20.2 Products offered 397 17.2 OTHER PLAYERS 398 17.2.1 WELLSTACK 398 17.2.2 RELATIENT 399 17.2.3 LUMA HEALTH INC. 400 17.2.4 CIPHERHEALTH INC. 401 17.2.5 YOSI HEALTH 402   18 RESEARCH METHODOLOGY 403 18.1 RESEARCH APPROACH 403 18.1.1 SECONDARY RESEARCH 403 18.1.1.1 Key secondary sources 404 18.1.1.2 Key data from secondary sources 405 18.1.2 PRIMARY RESEARCH 405 18.1.2.1 Primary sources 406 18.1.2.2 Key objectives of primary research 406 18.1.2.3 Key data from primary sources 407 18.1.2.4 Breakdown of primaries 407 18.1.2.5 Insights from primary experts 408 18.2 RESEARCH METHODOLOGY DESIGN 408 18.3 MARKET SIZE ESTIMATION 409 18.3.1 BOTTOM-UP APPROACH (REVENUE SHARE ANALYSIS) 409 18.3.2 TOP-DOWN OF PARENT MARKET ASSESSMENT 410 18.3.3 PRIMARY INTERVIEWS 410 18.3.4 TOP-DOWN APPROACH 410 18.4 DATA TRIANGULATION 415 18.5 MARKET SHARE ESTIMATION 415 18.6 STUDY ASSUMPTIONS 416 18.7 RESEARCH LIMITATIONS 416 18.8 RISK ANALYSIS 417 19 APPENDIX 418 19.1 DISCUSSION GUIDE 418 19.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 422 19.3 CUSTOMIZATION OPTIONS 424 19.4 RELATED REPORTS 424 19.5 AUTHOR DETAILS 425
圖表清單 List of Tables & Figures
TABLE 1 PATIENT ENGAGEMENT SOLUTIONS MARKET: INCLUSIONS & EXCLUSIONS 43 TABLE 2 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD 44 TABLE 3 IMPACT OF PORTER’S FIVE FORCES ON PATIENT ENGAGEMENT SOLUTIONS MARKET 63 TABLE 4 ROLE OF COMPANIES IN PATIENT ENGAGEMENT SOLUTIONS MARKET ECOSYSTEM 68 TABLE 5 INDICATIVE PRICE FOR PATIENT ENGAGEMENT SOLUTIONS, BY COMPONENT, 2025 (USD) 69 TABLE 6 INDICATIVE PRICE FOR PATIENT ENGAGEMENT SOLUTIONS, BY REGION, 2025 (USD) 70 TABLE 7 IMPORT SCENARIO FOR HS CODE 8528, 2021–2024 (USD THOUSAND) 71 TABLE 8 IMPORT SCENARIO FOR HS CODE 8741, 2021–2024 (USD THOUSAND) 71 TABLE 9 EXPORT SCENARIO FOR HS CODE 8528, 2021–2024 (USD THOUSAND) 72 TABLE 10 EXPORT SCENARIO FOR HS CODE 8471, 2021–2024 (USD THOUSAND) 73 TABLE 11 LIST OF KEY CONFERENCES AND EVENTS IN PATIENT ENGAGEMENT SOLUTIONS MARKET, JANUARY 2026–DECEMBER 2027 74 TABLE 12 CASE STUDY 1: ACHIEVING USD 15 MILLION IN SAVINGS BY REDUCING READMISSIONS WITH POST-DISCHARGE FOLLOW-UP 76 TABLE 13 CASE STUDY 2: BUILD TRUST THROUGH PATIENT ENGAGEMENT TECHNOLOGY: A CHILDREN’S HOSPITAL CASE STUDY 77 TABLE 14 CASE STUDY 3: IMPROVING PATIENT ENGAGEMENT AT SPARTA COMMUNITY HOSPITAL WITH TRUBRIDGE PATIENT CONNECT 77 TABLE 15 US-ADJUSTED RECIPROCAL TARIFF RATES 78 TABLE 16 JURISDICTION ANALYSIS OF TOP APPLICANT COUNTRIES FOR PATIENT ENGAGEMENT SOLUTIONS MARKET 87 TABLE 17 LIST OF PATENTS/PATENT APPLICATIONS IN PATIENT ENGAGEMENT SOLUTIONS MARKET 88 TABLE 18 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 96 TABLE 19 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 97 TABLE 20 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 98 TABLE 21 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 99 TABLE 22 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 100 TABLE 23 REGULATORY SCENARIO OF NORTH AMERICA 101 TABLE 24 REGULATORY SCENARIO OF EUROPE 102 TABLE 25 REGULATORY SCENARIO OF ASIA PACIFIC 102 TABLE 26 REGULATORY SCENARIO OF LATIN AMERICA 103 TABLE 27 REGULATORY SCENARIO OF MIDDLE EAST & AFRICA 104 TABLE 28 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS OF MAJOR END USERS (%) 106 TABLE 29 KEY BUYING CRITERIA FOR TOP THREE END USERS 107 TABLE 30 UNMET NEEDS IN PATIENT ENGAGEMENT SOLUTIONS MARKET 108 TABLE 31 END-USER EXPECTATIONS IN PATIENT ENGAGEMENT SOLUTIONS MARKET 109 TABLE 32 PATIENT ENGAGEMENT SOLUTIONS MARKET, BY COMPONENT, 2024–2031 (USD MILLION) 112 TABLE 33 LIST OF PRODUCTS OFFERED BY KEY PLAYERS IN PATIENT ENGAGEMENT HARDWARE MARKET 112 TABLE 34 PATIENT ENGAGEMENT HARDWARE MARKET, BY TYPE, 2024–2031 (USD MILLION) 113 TABLE 35 PATIENT ENGAGEMENT HARDWARE MARKET, BY REGION, 2024–2031 (USD MILLION) 113 TABLE 36 PATIENT ENGAGEMENT HARDWARE MARKET FOR IN-ROOM TELEVISIONS, BY REGION, 2024–2031 (USD MILLION) 114 TABLE 37 PATIENT ENGAGEMENT HARDWARE MARKET FOR INTEGRATED BEDSIDE TERMINALS/ASSISTED DEVICES, BY REGION, 2024–2031 (USD MILLION) 115 TABLE 38 PATIENT ENGAGEMENT HARDWARE MARKET FOR TABLETS, BY REGION, 2024–2031 (USD MILLION) 116 TABLE 39 LIST OF PRODUCTS OFFERED BY KEY PLAYERS IN PATIENT ENGAGEMENT SOFTWARE MARKET 116 TABLE 40 PATIENT ENGAGEMENT SOFTWARE MARKET, BY TYPE, 2024–2031 (USD MILLION) 117 TABLE 41 PATIENT ENGAGEMENT SOFTWARE MARKET, BY REGION, 2024–2031 (USD MILLION) 117 TABLE 42 PATIENT ENGAGEMENT SOFTWARE MARKET FOR PRE-CARE ENGAGEMENT, BY REGION, 2024–2031 (USD MILLION) 118 TABLE 43 PATIENT ENGAGEMENT SOFTWARE MARKET FOR POINT-OF-CARE ENGAGEMENT, BY REGION, 2024–2031 (USD MILLION) 119 TABLE 44 PATIENT ENGAGEMENT SOFTWARE MARKET FOR POST-CARE ENGAGEMENT, BY REGION, 2024–2031 (USD MILLION) 120 TABLE 45 LIST OF PRODUCTS OFFERED BY KEY PLAYERS IN PATIENT ENGAGEMENT SERVICES MARKET 121 TABLE 46 PATIENT ENGAGEMENT SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 121 TABLE 47 PATIENT ENGAGEMENT SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION) 121 TABLE 48 PATIENT ENGAGEMENT SERVICES MARKET FOR IMPLEMENTATION & INTEGRATION SERVICES, BY REGION, 2024–2031 (USD MILLION) 122 TABLE 49 PATIENT ENGAGEMENT SERVICES MARKET FOR TRAINING & EDUCATION SERVICES, BY REGION, 2024–2031 (USD MILLION) 123 TABLE 50 PATIENT ENGAGEMENT SERVICES MARKET FOR SUPPORT & MAINTENANCE SERVICES, BY REGION, 2024–2031 (USD MILLION) 124 TABLE 51 PATIENT ENGAGEMENT SERVICES MARKET FOR CONSULTING SERVICES, BY REGION, 2024–2031 (USD MILLION) 125 TABLE 52 PATIENT ENGAGEMENT SOLUTIONS MARKET, BY DELIVERY MODE, 2024–2031 (USD MILLION) 127 TABLE 53 KEY COMPANIES OFFERING ON-PREMISES PATIENT ENGAGEMENT SOLUTIONS 127 TABLE 54 ON-PREMISES PATIENT ENGAGEMENT SOLUTIONS MARKET, BY REGION, 2024–2031 (USD MILLION) 128 TABLE 55 KEY COMPANIES OFFERING CLOUD-BASED PATIENT ENGAGEMENT SOLUTIONS 128 TABLE 56 CLOUD-BASED PATIENT ENGAGEMENT SOLUTIONS MARKET, BY REGION, 2024–2031 (USD MILLION) 129 TABLE 57 PATIENT ENGAGEMENT SOLUTIONS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 131 TABLE 58 MAJOR PLAYERS OFFERING PATIENT ENGAGEMENT SOLUTIONS FOR CLINICAL CARE 132 TABLE 59 PATIENT ENGAGEMENT SOLUTIONS MARKET FOR CLINICAL CARE, BY REGION, 2024–2031 (USD MILLION) 132 TABLE 60 MAJOR PLAYERS OFFERING PATIENT ENGAGEMENT SOLUTIONS FOR CARE COORDINATION & COMMUNICATION 133 TABLE 61 PATIENT ENGAGEMENT SOLUTIONS MARKET FOR CARE COORDINATION & COMMUNICATION, BY REGION, 2024–2031 (USD MILLION) 133 TABLE 62 MAJOR PLAYERS OFFERING PATIENT ENGAGEMENT SOLUTIONS FOR HOME & REMOTE CARE 134 TABLE 63 PATIENT ENGAGEMENT SOLUTIONS MARKET FOR HOME & REMOTE CARE, BY REGION, 2024–2031 (USD MILLION) 134 TABLE 64 MAJOR PLAYERS OFFERING PATIENT ENGAGEMENT SOLUTIONS FOR POPULATION HEALTH & BEHAVIORAL ENGAGEMENT 135 TABLE 65 PATIENT ENGAGEMENT SOLUTIONS MARKET FOR POPULATION HEALTH & BEHAVIORAL ENGAGEMENT, BY REGION, 2024–2031 (USD MILLION) 136 TABLE 66 MAJOR PLAYERS OFFERING PATIENT ENGAGEMENT SOLUTIONS FOR FINANCIAL ENGAGEMENT 137 TABLE 67 PATIENT ENGAGEMENT SOLUTIONS MARKET FOR FINANCIAL ENGAGEMENT, BY REGION, 2024–2031 (USD MILLION) 137 TABLE 68 MAJOR PLAYERS OFFERING PATIENT ENGAGEMENT SOLUTIONS FOR OTHER APPLICATIONS 137 TABLE 69 PATIENT ENGAGEMENT SOLUTIONS MARKET FOR OTHER APPLICATIONS, BY REGION, 2024–2031 (USD MILLION) 138 TABLE 70 PATIENT ENGAGEMENT SOLUTIONS MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 140 TABLE 71 MAJOR PLAYERS OFFERING PATIENT ENGAGEMENT SOLUTIONS FOR CHRONIC DISEASES 141 TABLE 72 PATIENT ENGAGEMENT SOLUTIONS MARKET FOR CHRONIC DISEASES, BY TYPE, 2024–2031 (USD MILLION) 141 TABLE 73 PATIENT ENGAGEMENT SOLUTIONS MARKET FOR CHRONIC DISEASES, BY REGION, 2024–2031 (USD MILLION) 141 TABLE 74 PATIENT ENGAGEMENT SOLUTIONS MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2024–2031 (USD MILLION) 143 TABLE 75 PATIENT ENGAGEMENT SOLUTIONS MARKET FOR DIABETES, BY REGION, 2024–2031 (USD MILLION) 144 TABLE 76 PATIENT ENGAGEMENT SOLUTIONS MARKET FOR OBESITY, BY REGION, 2024–2031 (USD MILLION) 144 TABLE 77 PATIENT ENGAGEMENT SOLUTIONS MARKET FOR RESPIRATORY DISORDERS, BY REGION, 2024–2031 (USD MILLION) 145 TABLE 78 PATIENT ENGAGEMENT SOLUTIONS MARKET FOR ONCOLOGY, BY REGION, 2024–2031 (USD MILLION) 146 TABLE 79 PATIENT ENGAGEMENT SOLUTIONS MARKET FOR OTHER CHRONIC DISEASES, BY REGION, 2024–2031 (USD MILLION) 147 TABLE 80 MAJOR PLAYERS OFFERING PATIENT ENGAGEMENT SOLUTIONS FOR WOMEN’S HEALTH 148 TABLE 81 PATIENT ENGAGEMENT SOLUTIONS MARKET FOR WOMEN'S HEALTH, BY REGION, 2024–2031 (USD MILLION) 148 TABLE 82 MAJOR PLAYERS OFFERING PATIENT ENGAGEMENT SOLUTIONS FOR BEHAVIORAL & MENTAL HEALTH 149 TABLE 83 PATIENT ENGAGEMENT SOLUTIONS MARKET FOR BEHAVIORAL & MENTAL HEALTH, BY REGION, 2024–2031 (USD MILLION) 149 TABLE 84 MAJOR PLAYERS OFFERING PATIENT ENGAGEMENT SOLUTIONS FOR OTHER THERAPEUTIC AREAS 150 TABLE 85 PATIENT ENGAGEMENT SOLUTIONS MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2024–2031 (USD MILLION) 150 TABLE 86 PATIENT ENGAGEMENT SOLUTIONS MARKET, BY FUNCTIONALITY, 2024–2031 (USD MILLION) 152 TABLE 87 MAJOR COMPANIES OFFERING PATIENT ENGAGEMENT SOLUTIONS FOR PATIENT/CLIENT SCHEDULING 153 TABLE 88 PATIENT ENGAGEMENT SOLUTIONS MARKET FOR PATIENT/CLIENT SCHEDULING, BY REGION, 2024–2031 (USD MILLION) 153 TABLE 89 MAJOR COMPANIES OFFERING PATIENT ENGAGEMENT SOLUTIONS FOR TELEHEALTH 154 TABLE 90 PATIENT ENGAGEMENT SOLUTIONS MARKET FOR TELEHEALTH, BY REGION, 2024–2031 (USD MILLION) 154 TABLE 91 MAJOR COMPANIES OFFERING PATIENT ENGAGEMENT SOLUTIONS FOR E-PRESCRIBING 155 TABLE 92 PATIENT ENGAGEMENT SOLUTIONS MARKET FOR E-PRESCRIBING, BY REGION, 2024–2031 (USD MILLION) 155 TABLE 93 MAJOR COMPANIES OFFERING PATIENT ENGAGEMENT SOLUTIONS FOR DOCUMENT MANAGEMENT 156 TABLE 94 PATIENT ENGAGEMENT SOLUTIONS MARKET FOR DOCUMENT MANAGEMENT, BY REGION, 2024–2031 (USD MILLION) 156 TABLE 95 MAJOR COMPANIES OFFERING PATIENT ENGAGEMENT SOLUTIONS FOR BILLING & PAYMENTS 157 TABLE 96 PATIENT ENGAGEMENT SOLUTIONS MARKET FOR BILLING & PAYMENTS, BY REGION, 2024–2031 (USD MILLION) 157 TABLE 97 MAJOR COMPANIES OFFERING PATIENT ENGAGEMENT SOLUTIONS FOR PATIENT EDUCATION 158 TABLE 98 PATIENT ENGAGEMENT SOLUTIONS MARKET FOR PATIENT EDUCATION, BY REGION, 2024–2031 (USD MILLION) 158 TABLE 99 MAJOR COMPANIES OFFERING PATIENT ENGAGEMENT SOLUTIONS FOR OTHER FUNCTIONALITIES 159 TABLE 100 PATIENT ENGAGEMENT SOLUTIONS MARKET FOR OTHER FUNCTIONALITIES, BY REGION, 2024–2031 (USD MILLION) 159 TABLE 101 PATIENT ENGAGEMENT SOLUTIONS MARKET, BY END USER, 2024–2031 (USD MILLION) 161 TABLE 102 MAJOR COMPANIES OFFERING PATIENT ENGAGEMENT SOLUTIONS TO PAYERS 161 TABLE 103 PATIENT ENGAGEMENT SOLUTIONS MARKET FOR PROVIDERS, BY TYPE, 2024–2031 (USD MILLION) 162 TABLE 104 PATIENT ENGAGEMENT SOLUTIONS MARKET FOR PROVIDERS, BY REGION, 2024–2031 (USD MILLION) 162 TABLE 105 PATIENT ENGAGEMENT SOLUTIONS MARKET FOR HOSPITALS & HEALTHCARE SYSTEMS, BY REGION, 2024–2031 (USD MILLION) 163 TABLE 106 PATIENT ENGAGEMENT SOLUTIONS MARKET FOR ASCS, ACCS, AND OTHER OUTPATIENT SETTINGS, BY REGION, 2024–2031 (USD MILLION) 163 TABLE 107 PATIENT ENGAGEMENT SOLUTIONS MARKET FOR HOME HEALTHCARE PROVIDERS, BY REGION, 2024–2031 (USD MILLION) 164 TABLE 108 PATIENT ENGAGEMENT SOLUTIONS MARKET FOR OTHER PROVIDERS, BY REGION, 2024–2031 (USD MILLION) 165 TABLE 109 MAJOR COMPANIES OFFERING PATIENT ENGAGEMENT SOLUTIONS TO PAYERS 165 TABLE 110 PATIENT ENGAGEMENT SOLUTIONS MARKET FOR PAYERS, BY TYPE, 2024–2031 (USD MILLION) 166 TABLE 111 PATIENT ENGAGEMENT SOLUTIONS MARKET FOR PAYERS, BY REGION, 2024–2031 (USD MILLION) 166 TABLE 112 PATIENT ENGAGEMENT SOLUTIONS MARKET FOR PRIVATE PAYERS, BY REGION, 2024–2031 (USD MILLION) 167 TABLE 113 PATIENT ENGAGEMENT SOLUTIONS MARKET FOR PUBLIC PAYERS, BY REGION, 2024–2031 (USD MILLION) 167 TABLE 114 MAJOR COMPANIES OFFERING PATIENT ENGAGEMENT SOLUTIONS TO OTHER END USERS 168 TABLE 115 PATIENT ENGAGEMENT SOLUTIONS MARKET FOR OTHER END USERS, BY REGION, 2024–2031 (USD MILLION) 168 TABLE 116 PATIENT ENGAGEMENT SOLUTIONS MARKET, BY REGION, 2024–2031 (USD MILLION) 170 TABLE 117 NORTH AMERICA: KEY MACROINDICATORS 172 TABLE 118 NORTH AMERICA: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 173 TABLE 119 NORTH AMERICA: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY COMPONENT, 2024–2031 (USD MILLION) 173 TABLE 120 NORTH AMERICA: PATIENT ENGAGEMENT HARDWARE MARKET, BY TYPE, 2024–2031 (USD MILLION) 173 TABLE 121 NORTH AMERICA: PATIENT ENGAGEMENT SOFTWARE MARKET, BY TYPE, 2024–2031 (USD MILLION) 174 TABLE 122 NORTH AMERICA: PATIENT ENGAGEMENT SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 174 TABLE 123 NORTH AMERICA: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY DELIVERY MODE, 2024–2031 (USD MILLION) 174 TABLE 124 NORTH AMERICA: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 175 TABLE 125 NORTH AMERICA: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 175 TABLE 126 NORTH AMERICA: PATIENT ENGAGEMENT SOLUTIONS MARKET FOR CHRONIC DISEASES, BY TYPE, 2024–2031 (USD MILLION) 176 TABLE 127 NORTH AMERICA: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY FUNCTIONALITY, 2024–2031 (USD MILLION) 176 TABLE 128 NORTH AMERICA: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY END USER, 2024–2031 (USD MILLION) 177 TABLE 129 NORTH AMERICA: PATIENT ENGAGEMENT SOLUTIONS MARKET FOR PROVIDERS, BY TYPE, 2024–2031 (USD MILLION) 177 TABLE 130 NORTH AMERICA: PATIENT ENGAGEMENT SOLUTIONS MARKET FOR PAYERS, BY TYPE, 2024–2031 (USD MILLION) 177 TABLE 131 US: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY COMPONENT, 2024–2031 (USD MILLION) 178 TABLE 132 US: PATIENT ENGAGEMENT HARDWARE MARKET, BY TYPE, 2024–2031 (USD MILLION) 179 TABLE 133 US: PATIENT ENGAGEMENT SOFTWARE MARKET, BY TYPE, 2024–2031 (USD MILLION) 179 TABLE 134 US: PATIENT ENGAGEMENT SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 179 TABLE 135 US: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY DELIVERY MODE, 2024–2031 (USD MILLION) 180 TABLE 136 US: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 180 TABLE 137 US: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 180 TABLE 138 US: PATIENT ENGAGEMENT SOLUTIONS MARKET FOR CHRONIC DISEASES, BY TYPE, 2024–2031 (USD MILLION) 181 TABLE 139 US: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY FUNCTIONALITY, 2024–2031 (USD MILLION) 181 TABLE 140 US: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY END USER, 2024–2031 (USD MILLION) 182 TABLE 141 US: PATIENT ENGAGEMENT SOLUTIONS MARKET FOR PROVIDERS, BY TYPE, 2024–2031 (USD MILLION) 182 TABLE 142 US: PATIENT ENGAGEMENT SOLUTIONS MARKET FOR PAYERS, BY TYPE, 2024–2031 (USD MILLION) 182 TABLE 143 CANADA: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY COMPONENT, 2024–2031 (USD MILLION) 183 TABLE 144 CANADA: PATIENT ENGAGEMENT HARDWARE MARKET, BY TYPE, 2024–2031 (USD MILLION) 183 TABLE 145 CANADA: PATIENT ENGAGEMENT SOFTWARE MARKET, BY TYPE, 2024–2031 (USD MILLION) 184 TABLE 146 CANADA: PATIENT ENGAGEMENT SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 184 TABLE 147 CANADA: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY DELIVERY MODE, 2024–2031 (USD MILLION) 184 TABLE 148 CANADA: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 185 TABLE 149 CANADA: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 185 TABLE 150 CANADA: PATIENT ENGAGEMENT SOLUTIONS MARKET FOR CHRONIC DISEASES, BY TYPE, 2024–2031 (USD MILLION) 186 TABLE 151 CANADA: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY FUNCTIONALITY, 2024–2031 (USD MILLION) 186 TABLE 152 CANADA: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY END USER, 2024–2031 (USD MILLION) 187 TABLE 153 CANADA: PATIENT ENGAGEMENT SOLUTIONS MARKET FOR PROVIDERS, BY TYPE, 2024–2031 (USD MILLION) 187 TABLE 154 CANADA: PATIENT ENGAGEMENT SOLUTIONS MARKET FOR PAYERS, BY TYPE, 2024–2031 (USD MILLION) 187 TABLE 155 EUROPE: KEY MACROINDICATORS 189 TABLE 156 EUROPE: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 189 TABLE 157 EUROPE: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY COMPONENT, 2024–2031 (USD MILLION) 190 TABLE 158 EUROPE: PATIENT ENGAGEMENT HARDWARE MARKET, BY TYPE, 2024–2031 (USD MILLION) 190 TABLE 159 EUROPE: PATIENT ENGAGEMENT SOFTWARE MARKET, BY TYPE, 2024–2031 (USD MILLION) 190 TABLE 160 EUROPE: PATIENT ENGAGEMENT SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 191 TABLE 161 EUROPE: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY DELIVERY MODE, 2024–2031 (USD MILLION) 191 TABLE 162 EUROPE: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 191 TABLE 163 EUROPE: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 192 TABLE 164 EUROPE: PATIENT ENGAGEMENT SOLUTIONS MARKET FOR CHRONIC DISEASES, BY TYPE, 2024–2031 (USD MILLION) 192 TABLE 165 EUROPE: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY FUNCTIONALITY, 2024–2031 (USD MILLION) 193 TABLE 166 EUROPE: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY END USER, 2024–2031 (USD MILLION) 193 TABLE 167 EUROPE: PATIENT ENGAGEMENT SOLUTIONS MARKET FOR PROVIDERS, BY TYPE, 2024–2031 (USD MILLION) 194 TABLE 168 EUROPE: PATIENT ENGAGEMENT SOLUTIONS MARKET FOR PAYERS, BY TYPE, 2024–2031 (USD MILLION) 194 TABLE 169 GERMANY: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY COMPONENT, 2024–2031 (USD MILLION) 195 TABLE 170 GERMANY: PATIENT ENGAGEMENT HARDWARE MARKET, BY TYPE, 2024–2031 (USD MILLION) 195 TABLE 171 GERMANY: PATIENT ENGAGEMENT SOFTWARE MARKET, BY TYPE, 2024–2031 (USD MILLION) 196 TABLE 172 GERMANY: PATIENT ENGAGEMENT SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 196 TABLE 173 GERMANY: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY DELIVERY MODE, 2024–2031 (USD MILLION) 196 TABLE 174 GERMANY: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 197 TABLE 175 GERMANY: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 197 TABLE 176 GERMANY: PATIENT ENGAGEMENT SOLUTIONS MARKET FOR CHRONIC DISEASES, BY TYPE, 2024–2031 (USD MILLION) 198 TABLE 177 GERMANY: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY FUNCTIONALITY, 2024–2031 (USD MILLION) 198 TABLE 178 GERMANY: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY END USER, 2024–2031 (USD MILLION) 199 TABLE 179 GERMANY: PATIENT ENGAGEMENT SOLUTIONS MARKET FOR PROVIDERS, BY TYPE, 2024–2031 (USD MILLION) 199 TABLE 180 GERMANY: PATIENT ENGAGEMENT SOLUTIONS MARKET FOR PAYERS, BY TYPE, 2024–2031 (USD MILLION) 199 TABLE 181 FRANCE: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY COMPONENT, 2024–2031 (USD MILLION) 200 TABLE 182 FRANCE: PATIENT ENGAGEMENT HARDWARE MARKET, BY TYPE, 2024–2031 (USD MILLION) 201 TABLE 183 FRANCE: PATIENT ENGAGEMENT SOFTWARE MARKET, BY TYPE, 2024–2031 (USD MILLION) 201 TABLE 184 FRANCE: PATIENT ENGAGEMENT SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 201 TABLE 185 FRANCE: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY DELIVERY MODE, 2024–2031 (USD MILLION) 202 TABLE 186 FRANCE: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 202 TABLE 187 FRANCE: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 202 TABLE 188 FRANCE: PATIENT ENGAGEMENT SOLUTIONS MARKET FOR CHRONIC DISEASES, BY TYPE, 2024–2031 (USD MILLION) 203 TABLE 189 FRANCE: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY FUNCTIONALITY, 2024–2031 (USD MILLION) 203 TABLE 190 FRANCE: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY END USER, 2024–2031 (USD MILLION) 204 TABLE 191 FRANCE: PATIENT ENGAGEMENT SOLUTIONS MARKET FOR PROVIDERS, BY TYPE, 2024–2031 (USD MILLION) 204 TABLE 192 FRANCE: PATIENT ENGAGEMENT SOLUTIONS MARKET FOR PAYERS, BY TYPE, 2024–2031 (USD MILLION) 204 TABLE 193 UK: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY COMPONENT, 2024–2031 (USD MILLION) 205 TABLE 194 UK: PATIENT ENGAGEMENT HARDWARE MARKET, BY TYPE, 2024–2031 (USD MILLION) 206 TABLE 195 UK: PATIENT ENGAGEMENT SOFTWARE MARKET, BY TYPE, 2024–2031 (USD MILLION) 206 TABLE 196 UK: PATIENT ENGAGEMENT SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 206 TABLE 197 UK: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY DELIVERY MODE, 2024–2031 (USD MILLION) 207 TABLE 198 UK: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 207 TABLE 199 UK: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 207 TABLE 200 UK: PATIENT ENGAGEMENT SOLUTIONS MARKET FOR CHRONIC DISEASES, BY TYPE, 2024–2031 (USD MILLION) 208 TABLE 201 UK: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY FUNCTIONALITY, 2024–2031 (USD MILLION) 208 TABLE 202 UK: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY END USER, 2024–2031 (USD MILLION) 209 TABLE 203 UK: PATIENT ENGAGEMENT SOLUTIONS MARKET FOR PROVIDERS, BY TYPE, 2024–2031 (USD MILLION) 209 TABLE 204 UK: PATIENT ENGAGEMENT SOLUTIONS MARKET FOR PAYERS, BY TYPE, 2024–2031 (USD MILLION) 209 TABLE 205 ITALY: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY COMPONENT, 2024–2031 (USD MILLION) 211 TABLE 206 ITALY: PATIENT ENGAGEMENT HARDWARE MARKET, BY TYPE, 2024–2031 (USD MILLION) 211 TABLE 207 ITALY: PATIENT ENGAGEMENT SOFTWARE MARKET, BY TYPE, 2024–2031 (USD MILLION) 211 TABLE 208 ITALY: PATIENT ENGAGEMENT SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 212 TABLE 209 ITALY: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY DELIVERY MODE, 2024–2031 (USD MILLION) 212 TABLE 210 ITALY: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 212 TABLE 211 ITALY: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 213 TABLE 212 ITALY: PATIENT ENGAGEMENT SOLUTIONS MARKET FOR CHRONIC DISEASES, BY TYPE, 2024–2031 (USD MILLION) 213 TABLE 213 ITALY: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY FUNCTIONALITY, 2024–2031 (USD MILLION) 214 TABLE 214 ITALY: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY END USER, 2024–2031 (USD MILLION) 214 TABLE 215 ITALY: PATIENT ENGAGEMENT SOLUTIONS MARKET FOR PROVIDERS, BY TYPE, 2024–2031 (USD MILLION) 215 TABLE 216 ITALY: PATIENT ENGAGEMENT SOLUTIONS MARKET FOR PAYERS, BY TYPE, 2024–2031 (USD MILLION) 215 TABLE 217 SPAIN: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY COMPONENT, 2024–2031 (USD MILLION) 216 TABLE 218 SPAIN: PATIENT ENGAGEMENT HARDWARE MARKET, BY TYPE, 2024–2031 (USD MILLION) 216 TABLE 219 SPAIN: PATIENT ENGAGEMENT SOFTWARE MARKET, BY TYPE, 2024–2031 (USD MILLION) 216 TABLE 220 SPAIN: PATIENT ENGAGEMENT SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 217 TABLE 221 SPAIN: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY DELIVERY MODE, 2024–2031 (USD MILLION) 217 TABLE 222 SPAIN: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 217 TABLE 223 SPAIN: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 218 TABLE 224 SPAIN: PATIENT ENGAGEMENT SOLUTIONS MARKET FOR CHRONIC DISEASES, BY TYPE, 2024–2031 (USD MILLION) 218 TABLE 225 SPAIN: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY FUNCTIONALITY, 2024–2031 (USD MILLION) 219 TABLE 226 SPAIN: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY END USER, 2024–2031 (USD MILLION) 219 TABLE 227 SPAIN: PATIENT ENGAGEMENT SOLUTIONS MARKET FOR PROVIDERS, BY TYPE, 2024–2031 (USD MILLION) 220 TABLE 228 SPAIN: PATIENT ENGAGEMENT SOLUTIONS MARKET FOR PAYERS, BY TYPE, 2024–2031 (USD MILLION) 220 TABLE 229 REST OF EUROPE: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY COMPONENT, 2024–2031 (USD MILLION) 221 TABLE 230 REST OF EUROPE: PATIENT ENGAGEMENT HARDWARE MARKET, BY TYPE, 2024–2031 (USD MILLION) 221 TABLE 231 REST OF EUROPE: PATIENT ENGAGEMENT SOFTWARE MARKET, BY TYPE, 2024–2031 (USD MILLION) 222 TABLE 232 REST OF EUROPE: PATIENT ENGAGEMENT SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 222 TABLE 233 REST OF EUROPE: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY DELIVERY MODE, 2024–2031 (USD MILLION) 222 TABLE 234 REST OF EUROPE: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 223 TABLE 235 REST OF EUROPE: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 223 TABLE 236 REST OF EUROPE: PATIENT ENGAGEMENT SOLUTIONS MARKET FOR CHRONIC DISEASES, BY TYPE, 2024–2031 (USD MILLION) 224 TABLE 237 REST OF EUROPE: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY FUNCTIONALITY, 2024–2031 (USD MILLION) 224 TABLE 238 REST OF EUROPE: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY END USER, 2024–2031 (USD MILLION) 225 TABLE 239 REST OF EUROPE: PATIENT ENGAGEMENT SOLUTIONS MARKET FOR PROVIDERS, BY TYPE, 2024–2031 (USD MILLION) 225 TABLE 240 REST OF EUROPE: PATIENT ENGAGEMENT SOLUTIONS MARKET FOR PAYERS, BY TYPE, 2024–2031 (USD MILLION) 225 TABLE 241 ASIA PACIFIC: KEY MACROINDICATORS 227 TABLE 242 ASIA PACIFIC: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 228 TABLE 243 ASIA PACIFIC: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY COMPONENT, 2024–2031 (USD MILLION) 228 TABLE 244 ASIA PACIFIC: PATIENT ENGAGEMENT HARDWARE MARKET, BY TYPE, 2024–2031 (USD MILLION) 228 TABLE 245 ASIA PACIFIC: PATIENT ENGAGEMENT SOFTWARE MARKET, BY TYPE, 2024–2031 (USD MILLION) 229 TABLE 246 ASIA PACIFIC: PATIENT ENGAGEMENT SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 229 TABLE 247 ASIA PACIFIC: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY DELIVERY MODE, 2024–2031 (USD MILLION) 229 TABLE 248 ASIA PACIFIC: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 230 TABLE 249 ASIA PACIFIC: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 230 TABLE 250 ASIA PACIFIC: PATIENT ENGAGEMENT SOLUTIONS MARKET FOR CHRONIC DISEASES, BY TYPE, 2024–2031 (USD MILLION) 231 TABLE 251 ASIA PACIFIC: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY FUNCTIONALITY, 2024–2031 (USD MILLION) 231 TABLE 252 ASIA PACIFIC: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY END USER, 2024–2031 (USD MILLION) 232 TABLE 253 ASIA PACIFIC: PATIENT ENGAGEMENT SOLUTIONS MARKET FOR PROVIDERS, BY TYPE, 2024–2031 (USD MILLION) 232 TABLE 254 ASIA PACIFIC: PATIENT ENGAGEMENT SOLUTIONS MARKET FOR PAYERS, BY TYPE, 2024–2031 (USD MILLION) 232 TABLE 255 CHINA: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY COMPONENT, 2024–2031 (USD MILLION) 233 TABLE 256 CHINA: PATIENT ENGAGEMENT HARDWARE MARKET, BY TYPE, 2024–2031 (USD MILLION) 233 TABLE 257 CHINA: PATIENT ENGAGEMENT SOFTWARE MARKET, BY TYPE, 2024–2031 (USD MILLION) 234 TABLE 258 CHINA: PATIENT ENGAGEMENT SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 234 TABLE 259 CHINA: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY DELIVERY MODE, 2024–2031 (USD MILLION) 234 TABLE 260 CHINA: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 235 TABLE 261 CHINA: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 235 TABLE 262 CHINA: PATIENT ENGAGEMENT SOLUTIONS MARKET FOR CHRONIC DISEASES, BY TYPE, 2024–2031 (USD MILLION) 236 TABLE 263 CHINA: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY FUNCTIONALITY, 2024–2031 (USD MILLION) 236 TABLE 264 CHINA: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY END USER, 2024–2031 (USD MILLION) 237 TABLE 265 CHINA: PATIENT ENGAGEMENT SOLUTIONS MARKET FOR PROVIDERS, BY TYPE, 2024–2031 (USD MILLION) 237 TABLE 266 CHINA: PATIENT ENGAGEMENT SOLUTIONS MARKET FOR PAYERS, BY TYPE, 2024–2031 (USD MILLION) 237 TABLE 267 JAPAN: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY COMPONENT, 2024–2031 (USD MILLION) 238 TABLE 268 JAPAN: PATIENT ENGAGEMENT HARDWARE MARKET, BY TYPE, 2024–2031 (USD MILLION) 238 TABLE 269 JAPAN: PATIENT ENGAGEMENT SOFTWARE MARKET, BY TYPE, 2024–2031 (USD MILLION) 239 TABLE 270 JAPAN: PATIENT ENGAGEMENT SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 239 TABLE 271 JAPAN: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY DELIVERY MODE, 2024–2031 (USD MILLION) 239 TABLE 272 JAPAN: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 240 TABLE 273 JAPAN: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 240 TABLE 274 JAPAN: PATIENT ENGAGEMENT SOLUTIONS MARKET FOR CHRONIC DISEASES, BY TYPE, 2024–2031 (USD MILLION) 241 TABLE 275 JAPAN: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY FUNCTIONALITY, 2024–2031 (USD MILLION) 241 TABLE 276 JAPAN: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY END USER, 2024–2031 (USD MILLION) 242 TABLE 277 JAPAN: PATIENT ENGAGEMENT SOLUTIONS MARKET FOR PROVIDERS, BY TYPE, 2024–2031 (USD MILLION) 242 TABLE 278 JAPAN: PATIENT ENGAGEMENT SOLUTIONS MARKET FOR PAYERS, BY TYPE, 2024–2031 (USD MILLION) 242 TABLE 279 INDIA: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY COMPONENT, 2024–2031 (USD MILLION) 243 TABLE 280 INDIA: PATIENT ENGAGEMENT HARDWARE MARKET, BY TYPE, 2024–2031 (USD MILLION) 244 TABLE 281 INDIA: PATIENT ENGAGEMENT SOFTWARE MARKET, BY TYPE, 2024–2031 (USD MILLION) 244 TABLE 282 INDIA: PATIENT ENGAGEMENT SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 244 TABLE 283 INDIA: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY DELIVERY MODE, 2024–2031 (USD MILLION) 245 TABLE 284 INDIA: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 245 TABLE 285 INDIA: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 245 TABLE 286 INDIA: PATIENT ENGAGEMENT SOLUTIONS MARKET FOR CHRONIC DISEASES, BY TYPE, 2024–2031 (USD MILLION) 246 TABLE 287 INDIA: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY FUNCTIONALITY, 2024–2031 (USD MILLION) 246 TABLE 288 INDIA: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY END USER, 2024–2031 (USD MILLION) 247 TABLE 289 INDIA: PATIENT ENGAGEMENT SOLUTIONS MARKET FOR PROVIDERS, BY TYPE, 2024–2031 (USD MILLION) 247 TABLE 290 INDIA: PATIENT ENGAGEMENT SOLUTIONS MARKET FOR PAYERS, BY TYPE, 2024–2031 (USD MILLION) 247 TABLE 291 SOUTH KOREA: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY COMPONENT, 2024–2031 (USD MILLION) 248 TABLE 292 SOUTH KOREA: PATIENT ENGAGEMENT HARDWARE MARKET, BY TYPE, 2024–2031 (USD MILLION) 249 TABLE 293 SOUTH KOREA: PATIENT ENGAGEMENT SOFTWARE MARKET, BY TYPE, 2024–2031 (USD MILLION) 249 TABLE 294 SOUTH KOREA: PATIENT ENGAGEMENT SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 249 TABLE 295 SOUTH KOREA: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY DELIVERY MODE, 2024–2031 (USD MILLION) 250 TABLE 296 SOUTH KOREA: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 250 TABLE 297 SOUTH KOREA: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 250 TABLE 298 SOUTH KOREA: PATIENT ENGAGEMENT SOLUTIONS MARKET FOR CHRONIC DISEASES, BY TYPE, 2024–2031 (USD MILLION) 251 TABLE 299 SOUTH KOREA: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY FUNCTIONALITY, 2024–2031 (USD MILLION) 251 TABLE 300 SOUTH KOREA: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY END USER, 2024–2031 (USD MILLION) 252 TABLE 301 SOUTH KOREA: PATIENT ENGAGEMENT SOLUTIONS MARKET FOR PROVIDERS, BY TYPE, 2024–2031 (USD MILLION) 252 TABLE 302 SOUTH KOREA: PATIENT ENGAGEMENT SOLUTIONS MARKET FOR PAYERS, BY TYPE, 2024–2031 (USD MILLION) 252 TABLE 303 AUSTRALIA: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY COMPONENT, 2024–2031 (USD MILLION) 254 TABLE 304 AUSTRALIA: PATIENT ENGAGEMENT HARDWARE MARKET, BY TYPE, 2024–2031 (USD MILLION) 254 TABLE 305 AUSTRALIA: PATIENT ENGAGEMENT SOFTWARE MARKET, BY TYPE, 2024–2031 (USD MILLION) 254 TABLE 306 AUSTRALIA: PATIENT ENGAGEMENT SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 255 TABLE 307 AUSTRALIA: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY DELIVERY MODE, 2024–2031 (USD MILLION) 255 TABLE 308 AUSTRALIA: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 255 TABLE 309 AUSTRALIA: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 256 TABLE 310 AUSTRALIA: PATIENT ENGAGEMENT SOLUTIONS MARKET FOR CHRONIC DISEASES, BY TYPE, 2024–2031 (USD MILLION) 256 TABLE 311 AUSTRALIA: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY FUNCTIONALITY, 2024–2031 (USD MILLION) 257 TABLE 312 AUSTRALIA: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY END USER, 2024–2031 (USD MILLION) 257 TABLE 313 AUSTRALIA: PATIENT ENGAGEMENT SOLUTIONS MARKET FOR PROVIDERS, BY TYPE, 2024–2031 (USD MILLION) 258 TABLE 314 AUSTRALIA: PATIENT ENGAGEMENT SOLUTIONS MARKET FOR PAYERS, BY TYPE, 2024–2031 (USD MILLION) 258 TABLE 315 REST OF ASIA PACIFIC: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY COMPONENT, 2024–2031 (USD MILLION) 259 TABLE 316 REST OF ASIA PACIFIC: PATIENT ENGAGEMENT HARDWARE MARKET, BY TYPE, 2024–2031 (USD MILLION) 259 TABLE 317 REST OF ASIA PACIFIC: PATIENT ENGAGEMENT SOFTWARE MARKET, BY TYPE, 2024–2031 (USD MILLION) 260 TABLE 318 REST OF ASIA PACIFIC: PATIENT ENGAGEMENT SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 260 TABLE 319 REST OF ASIA PACIFIC: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY DELIVERY MODE, 2024–2031 (USD MILLION) 260 TABLE 320 REST OF ASIA PACIFIC: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 261 TABLE 321 REST OF ASIA PACIFIC: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 261 TABLE 322 REST OF ASIA PACIFIC: PATIENT ENGAGEMENT SOLUTIONS MARKET FOR CHRONIC DISEASES, BY TYPE, 2024–2031 (USD MILLION) 262 TABLE 323 REST OF ASIA PACIFIC: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY FUNCTIONALITY, 2024–2031 (USD MILLION) 262 TABLE 324 REST OF ASIA PACIFIC: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY END USER, 2024–2031 (USD MILLION) 263 TABLE 325 REST OF ASIA PACIFIC: PATIENT ENGAGEMENT SOLUTIONS MARKET FOR PROVIDERS, BY TYPE, 2024–2031 (USD MILLION) 263 TABLE 326 REST OF ASIA PACIFIC: PATIENT ENGAGEMENT SOLUTIONS MARKET FOR PAYERS, BY TYPE, 2024–2031 (USD MILLION) 263 TABLE 327 LATIN AMERICA: KEY MACROINDICATORS 265 TABLE 328 LATIN AMERICA: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 265 TABLE 329 LATIN AMERICA: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY COMPONENT, 2024–2031 (USD MILLION) 265 TABLE 330 LATIN AMERICA: PATIENT ENGAGEMENT HARDWARE MARKET, BY TYPE, 2024–2031 (USD MILLION) 266 TABLE 331 LATIN AMERICA: PATIENT ENGAGEMENT SOFTWARE MARKET, BY TYPE, 2024–2031 (USD MILLION) 266 TABLE 332 LATIN AMERICA: PATIENT ENGAGEMENT SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 266 TABLE 333 LATIN AMERICA: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY DELIVERY MODE, 2024–2031 (USD MILLION) 267 TABLE 334 LATIN AMERICA: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 267 TABLE 335 LATIN AMERICA: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY THERPEUTIC AREA, 2024–2031 (USD MILLION) 267 TABLE 336 LATIN AMERICA: PATIENT ENGAGEMENT SOLUTIONS MARKET FOR CHRONIC DISEASES, BY TYPE, 2024–2031 (USD MILLION) 268 TABLE 337 LATIN AMERICA: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY FUNCTIONALITY, 2024–2031 (USD MILLION) 268 TABLE 338 LATIN AMERICA: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY END USER, 2024–2031 (USD MILLION) 269 TABLE 339 LATIN AMERICA: PATIENT ENGAGEMENT SOLUTIONS MARKET FOR PROVIDERS, BY TYPE, 2024–2031 (USD MILLION) 269 TABLE 340 LATIN AMERICA: PATIENT ENGAGEMENT SOLUTIONS MARKET FOR PAYERS, BY TYPE, 2024–2031 (USD MILLION) 269 TABLE 341 BRAZIL: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY COMPONENT, 2024–2031 (USD MILLION) 270 TABLE 342 BRAZIL: PATIENT ENGAGEMENT HARDWARE MARKET, BY TYPE, 2024–2031 (USD MILLION) 271 TABLE 343 BRAZIL: PATIENT ENGAGEMENT SOFTWARE MARKET, BY TYPE, 2024–2031 (USD MILLION) 271 TABLE 344 BRAZIL: PATIENT ENGAGEMENT SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 271 TABLE 345 BRAZIL: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY DELIVERY MODE, 2024–2031 (USD MILLION) 272 TABLE 346 BRAZIL: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 272 TABLE 347 BRAZIL: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY THERPEUTIC AREA, 2024–2031 (USD MILLION) 272 TABLE 348 BRAZIL: PATIENT ENGAGEMENT SOLUTIONS MARKET FOR CHRONIC DISEASES, BY TYPE, 2024–2031 (USD MILLION) 273 TABLE 349 BRAZIL: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY FUNCTIONALITY, 2024–2031 (USD MILLION) 273 TABLE 350 BRAZIL: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY END USER, 2024–2031 (USD MILLION) 274 TABLE 351 BRAZIL: PATIENT ENGAGEMENT SOLUTIONS MARKET FOR PROVIDERS, BY TYPE, 2024–2031 (USD MILLION) 274 TABLE 352 BRAZIL: PATIENT ENGAGEMENT SOLUTIONS MARKET FOR PAYERS, BY TYPE, 2024–2031 (USD MILLION) 274 TABLE 353 MEXICO: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY COMPONENT, 2024–2031 (USD MILLION) 275 TABLE 354 MEXICO: PATIENT ENGAGEMENT HARDWARE MARKET, BY TYPE, 2024–2031 (USD MILLION) 276 TABLE 355 MEXICO: PATIENT ENGAGEMENT SOFTWARE MARKET, BY TYPE, 2024–2031 (USD MILLION) 276 TABLE 356 MEXICO: PATIENT ENGAGEMENT SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 276 TABLE 357 MEXICO: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY DELIVERY MODE, 2024–2031 (USD MILLION) 277 TABLE 358 MEXICO: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 277 TABLE 359 MEXICO: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY THERPEUTIC AREA, 2024–2031 (USD MILLION) 277 TABLE 360 MEXICO: PATIENT ENGAGEMENT SOLUTIONS MARKET FOR CHRONIC DISEASES, BY TYPE, 2024–2031 (USD MILLION) 278 TABLE 361 MEXICO: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY FUNCTIONALITY, 2024–2031 (USD MILLION) 278 TABLE 362 MEXICO: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY END USER, 2024–2031 (USD MILLION) 279 TABLE 363 MEXICO: PATIENT ENGAGEMENT SOLUTIONS MARKET FOR PROVIDERS, BY TYPE, 2024–2031 (USD MILLION) 279 TABLE 364 MEXICO: PATIENT ENGAGEMENT SOLUTIONS MARKET FOR PAYERS, BY TYPE, 2024–2031 (USD MILLION) 279 TABLE 365 REST OF LATIN AMERICA: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY COMPONENT, 2024–2031 (USD MILLION) 280 TABLE 366 REST OF LATIN AMERICA: PATIENT ENGAGEMENT HARDWARE MARKET, BY TYPE, 2024–2031 (USD MILLION) 281 TABLE 367 REST OF LATIN AMERICA: PATIENT ENGAGEMENT SOFTWARE MARKET, BY TYPE, 2024–2031 (USD MILLION) 281 TABLE 368 REST OF LATIN AMERICA: PATIENT ENGAGEMENT SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 281 TABLE 369 REST OF LATIN AMERICA: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY DELIVERY MODE, 2024–2031 (USD MILLION) 282 TABLE 370 REST OF LATIN AMERICA: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 282 TABLE 371 REST OF LATIN AMERICA: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY THERPEUTIC AREA, 2024–2031 (USD MILLION) 282 TABLE 372 REST OF LATIN AMERICA: PATIENT ENGAGEMENT SOLUTIONS MARKET FOR CHRONIC DISEASES, BY TYPE, 2024–2031 (USD MILLION) 283 TABLE 373 REST OF LATIN AMERICA: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY FUNCTIONALITY, 2024–2031 (USD MILLION) 283 TABLE 374 REST OF LATIN AMERICA: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY END USER, 2024–2031 (USD MILLION) 284 TABLE 375 REST OF LATIN AMERICA: PATIENT ENGAGEMENT SOLUTIONS MARKET FOR PROVIDERS, BY TYPE, 2024–2031 (USD MILLION) 284 TABLE 376 REST OF LATIN AMERICA: PATIENT ENGAGEMENT SOLUTIONS MARKET FOR PAYERS, BY TYPE, 2024–2031 (USD MILLION) 284 TABLE 377 MIDDLE EAST & AFRICA: KEY MACROINDICATORS 286 TABLE 378 MIDDLE EAST & AFRICA: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY REGION, 2024–2031 (USD MILLION) 286 TABLE 379 MIDDLE EAST & AFRICA: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY COMPONENT, 2024–2031 (USD MILLION) 286 TABLE 380 MIDDLE EAST & AFRICA: PATIENT ENGAGEMENT HARDWARE MARKET, BY TYPE, 2024–2031 (USD MILLION) 287 TABLE 381 MIDDLE EAST & AFRICA: PATIENT ENGAGEMENT SOFTWARE MARKET, BY TYPE, 2024–2031 (USD MILLION) 287 TABLE 382 MIDDLE EAST & AFRICA: PATIENT ENGAGEMENT SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 287 TABLE 383 MIDDLE EAST & AFRICA: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY DELIVERY MODE, 2024–2031 (USD MILLION) 288 TABLE 384 MIDDLE EAST & AFRICA: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 288 TABLE 385 MIDDLE EAST & AFRICA: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY THERPEUTIC AREA, 2024–2031 (USD MILLION) 288 TABLE 386 MIDDLE EAST & AFRICA: PATIENT ENGAGEMENT SOLUTIONS MARKET FOR CHRONIC DISEASES, BY TYPE, 2024–2031 (USD MILLION) 289 TABLE 387 MIDDLE EAST & AFRICA: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY FUNCTIONALITY, 2024–2031 (USD MILLION) 289 TABLE 388 MIDDLE EAST & AFRICA: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY END USER, 2024–2031 (USD MILLION) 289 TABLE 389 MIDDLE EAST & AFRICA: PATIENT ENGAGEMENT SOLUTIONS MARKET FOR PROVIDERS, BY TYPE, 2024–2031 (USD MILLION) 290 TABLE 390 MIDDLE EAST & AFRICA: PATIENT ENGAGEMENT SOLUTIONS MARKET FOR PAYERS, BY TYPE, 2024–2031 (USD MILLION) 290 TABLE 391 GCC COUNTRIES: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 291 TABLE 392 GCC COUNTRIES: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY COMPONENT, 2024–2031 (USD MILLION) 291 TABLE 393 GCC COUNTRIES: PATIENT ENGAGEMENT HARDWARE MARKET, BY TYPE, 2024–2031 (USD MILLION) 292 TABLE 394 GCC COUNTRIES: PATIENT ENGAGEMENT SOFTWARE MARKET, BY TYPE, 2024–2031 (USD MILLION) 292 TABLE 395 GCC COUNTRIES: PATIENT ENGAGEMENT SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 292 TABLE 396 GCC COUNTRIES: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY DELIVERY MODE, 2024–2031 (USD MILLION) 293 TABLE 397 GCC COUNTRIES: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 293 TABLE 398 GCC COUNTRIES: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY THERPEUTIC AREA, 2024–2031 (USD MILLION) 293 TABLE 399 GCC COUNTRIES: PATIENT ENGAGEMENT SOLUTIONS MARKET FOR CHRONIC DISEASES, BY TYPE, 2024–2031 (USD MILLION) 294 TABLE 400 GCC COUNTRIES: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY FUNCTIONALITY, 2024–2031 (USD MILLION) 294 TABLE 401 GCC COUNTRIES: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY END USER, 2024–2031 (USD MILLION) 294 TABLE 402 GCC COUNTRIES: PATIENT ENGAGEMENT SOLUTIONS MARKET FOR PROVIDERS, BY TYPE, 2024–2031 (USD MILLION) 295 TABLE 403 GCC COUNTRIES: PATIENT ENGAGEMENT SOLUTIONS MARKET FOR PAYERS, BY TYPE, 2024–2031 (USD MILLION) 295 TABLE 404 KINGDOM OF SAUDI ARABIA: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY COMPONENT, 2024–2031 (USD MILLION) 296 TABLE 405 KINGDOM OF SAUDI ARABIA: PATIENT ENGAGEMENT HARDWARE MARKET, BY TYPE, 2024–2031 (USD MILLION) 296 TABLE 406 KINGDOM OF SAUDI ARABIA: PATIENT ENGAGEMENT SOFTWARE MARKET, BY TYPE, 2024–2031 (USD MILLION) 296 TABLE 407 KINGDOM OF SAUDI ARABIA: PATIENT ENGAGEMENT SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 297 TABLE 408 KINGDOM OF SAUDI ARABIA: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY DELIVERY MODE, 2024–2031 (USD MILLION) 297 TABLE 409 KINGDOM OF SAUDI ARABIA: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 297 TABLE 410 KINGDOM OF SAUDI ARABIA: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 298 TABLE 411 KINGDOM OF SAUDI ARABIA: PATIENT ENGAGEMENT SOLUTIONS MARKET FOR CHRONIC DISEASES, BY TYPE, 2024–2031 (USD MILLION) 298 TABLE 412 KINGDOM OF SAUDI ARABIA: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY FUNCTIONALITY, 2024–2031 (USD MILLION) 299 TABLE 413 KINGDOM OF SAUDI ARABIA: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY END USER, 2024–2031 (USD MILLION) 299 TABLE 414 KINGDOM OF SAUDI ARABIA: PATIENT ENGAGEMENT SOLUTIONS MARKET FOR PROVIDERS, BY TYPE, 2024–2031 (USD MILLION) 299 TABLE 415 KINGDOM OF SAUDI ARABIA: PATIENT ENGAGEMENT SOLUTIONS MARKET FOR PAYERS, BY TYPE, 2024–2031 (USD MILLION) 300 TABLE 416 UAE: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY COMPONENT, 2024–2031 (USD MILLION) 300 TABLE 417 UAE: PATIENT ENGAGEMENT HARDWARE MARKET, BY TYPE, 2024–2031 (USD MILLION) 301 TABLE 418 UAE: PATIENT ENGAGEMENT SOFTWARE MARKET, BY TYPE, 2024–2031 (USD MILLION) 301 TABLE 419 UAE: PATIENT ENGAGEMENT SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 301 TABLE 420 UAE: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY DELIVERY MODE, 2024–2031 (USD MILLION) 302 TABLE 421 UAE: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 302 TABLE 422 UAE: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY THERPEUTIC AREA, 2024–2031 (USD MILLION) 302 TABLE 423 UAE: PATIENT ENGAGEMENT SOLUTIONS MARKET FOR CHRONIC DISEASES, BY TYPE, 2024–2031 (USD MILLION) 303 TABLE 424 UAE: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY FUNCTIONALITY, 2024–2031 (USD MILLION) 303 TABLE 425 UAE: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY END USER, 2024–2031 (USD MILLION) 304 TABLE 426 UAE: PATIENT ENGAGEMENT SOLUTIONS MARKET FOR PROVIDERS, BY TYPE, 2024–2031 (USD MILLION) 304 TABLE 427 UAE: PATIENT ENGAGEMENT SOLUTIONS MARKET FOR PAYERS, BY TYPE, 2024–2031 (USD MILLION) 304 TABLE 428 REST OF GCC COUNTRIES: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY COMPONENT, 2024–2031 (USD MILLION) 305 TABLE 429 REST OF GCC COUNTRIES: PATIENT ENGAGEMENT HARDWARE MARKET, BY TYPE, 2024–2031 (USD MILLION) 305 TABLE 430 REST OF GCC COUNTRIES: PATIENT ENGAGEMENT SOFTWARE MARKET, BY TYPE, 2024–2031 (USD MILLION) 306 TABLE 431 REST OF GCC COUNTRIES: PATIENT ENGAGEMENT SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 306 TABLE 432 REST OF GCC COUNTRIES: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY DELIVERY MODE, 2024–2031 (USD MILLION) 306 TABLE 433 REST OF GCC COUNTRIES: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 307 TABLE 434 REST OF GCC COUNTRIES: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY THERPEUTIC AREA, 2024–2031 (USD MILLION) 307 TABLE 435 REST OF GCC COUNTRIES: PATIENT ENGAGEMENT SOLUTIONS MARKET FOR CHRONIC DISEASES, BY TYPE, 2024–2031 (USD MILLION) 308 TABLE 436 REST OF GCC COUNTRIES: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY FUNCTIONALITY, 2024–2031 (USD MILLION) 308 TABLE 437 REST OF GCC COUNTRIES: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY END USER, 2024–2031 (USD MILLION) 308 TABLE 438 REST OF GCC COUNTRIES: PATIENT ENGAGEMENT SOLUTIONS MARKET FOR PROVIDERS, BY TYPE, 2024–2031 (USD MILLION) 309 TABLE 439 REST OF GCC COUNTRIES: PATIENT ENGAGEMENT SOLUTIONS MARKET FOR PAYERS, BY TYPE, 2024–2031 (USD MILLION) 309 TABLE 440 SOUTH AFRICA: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY COMPONENT, 2024–2031 (USD MILLION) 310 TABLE 441 SOUTH AFRICA: PATIENT ENGAGEMENT HARDWARE MARKET, BY TYPE, 2024–2031 (USD MILLION) 310 TABLE 442 SOUTH AFRICA: PATIENT ENGAGEMENT SOFTWARE MARKET, BY TYPE, 2024–2031 (USD MILLION) 311 TABLE 443 SOUTH AFRICA: PATIENT ENGAGEMENT SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 311 TABLE 444 SOUTH AFRICA: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY DELIVERY MODE, 2024–2031 (USD MILLION) 311 TABLE 445 SOUTH AFRICA: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 312 TABLE 446 SOUTH AFRICA: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY THERPEUTIC AREA, 2024–2031 (USD MILLION) 312 TABLE 447 SOUTH AFRICA: PATIENT ENGAGEMENT SOLUTIONS MARKET FOR CHRONIC DISEASES, BY TYPE, 2024–2031 (USD MILLION) 313 TABLE 448 SOUTH AFRICA: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY FUNCTIONALITY, 2024–2031 (USD MILLION) 313 TABLE 449 SOUTH AFRICA: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY END USER, 2024–2031 (USD MILLION) 313 TABLE 450 SOUTH AFRICA: PATIENT ENGAGEMENT SOLUTIONS MARKET FOR PROVIDERS, BY TYPE, 2024–2031 (USD MILLION) 314 TABLE 451 SOUTH AFRICA: PATIENT ENGAGEMENT SOLUTIONS MARKET FOR PAYERS, BY TYPE, 2024–2031 (USD MILLION) 314 TABLE 452 REST OF MIDDLE EAST & AFRICA: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY COMPONENT, 2024–2031 (USD MILLION) 315 TABLE 453 REST OF MIDDLE EAST & AFRICA: PATIENT ENGAGEMENT HARDWARE MARKET, BY TYPE, 2024–2031 (USD MILLION) 315 TABLE 454 REST OF MIDDLE EAST & AFRICA: PATIENT ENGAGEMENT SOFTWARE MARKET, BY TYPE, 2024–2031 (USD MILLION) 316 TABLE 455 REST OF MIDDLE EAST & AFRICA: PATIENT ENGAGEMENT SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 316 TABLE 456 REST OF MIDDLE EAST & AFRICA: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY DELIVERY MODE, 2024–2031 (USD MILLION) 316 TABLE 457 REST OF MIDDLE EAST & AFRICA: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 317 TABLE 458 REST OF MIDDLE EAST & AFRICA: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY THERPEUTIC AREA, 2024–2031 (USD MILLION) 317 TABLE 459 REST OF MIDDLE EAST & AFRICA: PATIENT ENGAGEMENT SOLUTIONS MARKET FOR CHRONIC DISEASES, BY TYPE, 2024–2031 (USD MILLION) 318 TABLE 460 REST OF MIDDLE EAST & AFRICA: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY FUNCTIONALITY, 2024–2031 (USD MILLION) 318 TABLE 461 REST OF MIDDLE EAST & AFRICA: PATIENT ENGAGEMENT SOLUTIONS MARKET, BY END USER, 2024–2031 (USD MILLION) 318 TABLE 462 REST OF MIDDLE EAST & AFRICA: PATIENT ENGAGEMENT SOLUTIONS MARKET FOR PROVIDERS, BY TYPE, 2024–2031 (USD MILLION) 319 TABLE 463 REST OF MIDDLE EAST & AFRICA: PATIENT ENGAGEMENT SOLUTIONS MARKET FOR PAYERS, BY TYPE, 2024–2031 (USD MILLION) 319 TABLE 464 OVERVIEW OF MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN PATIENT ENGAGEMENT SOLUTIONS MARKET, JANUARY 2022–FEBRUARY 2026 320 TABLE 465 PATIENT ENGAGEMENT SOLUTIONS MARKET: DEGREE OF COMPETITION 324 TABLE 466 PATIENT ENGAGEMENT SOLUTIONS MARKET: REGION FOOTPRINT 330 TABLE 467 PATIENT ENGAGEMENT SOLUTIONS MARKET: COMPONENT FOOTPRINT 331 TABLE 468 PATIENT ENGAGEMENT SOLUTIONS MARKET: APPLICATION FOOTPRINT 332 TABLE 469 PATIENT ENGAGEMENT SOLUTIONS MARKET: END-USER FOOTPRINT 333 TABLE 470 PATIENT ENGAGEMENT SOLUTIONS MARKET: DETAILED LIST OF KEY STARTUP/SME PLAYERS 335 TABLE 471 PATIENT ENGAGEMENT SOLUTIONS MARKET: COMPETITIVE BENCHMARKING OF KEY PLAYERS/STARTUP PLAYERS, BY REGION 335 TABLE 472 PATIENT ENGAGEMENT SOLUTIONS MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS, BY COMPONENT 336 TABLE 473 PATIENT ENGAGEMENT SOLUTIONS MARKET: PRODUCT LAUNCHES & ENHANCEMENTS, JANUARY 2022–FEBRUARY 2026 336 TABLE 474 PATIENT ENGAGEMENT SOLUTIONS MARKET: DEALS, JANUARY 2022–FEBRUARY 2026 337 TABLE 475 PATIENT ENGAGEMENT SOLUTIONS MARKET: EXPANSIONS, JANUARY 2022–FEBRUARY 2026 338 TABLE 476 PATIENT ENGAGEMENT SOLUTIONS MARKET: OTHER DEVELOPMENTS, JANUARY 2022–FEBRUARY 2026 338 TABLE 477 MCKESSON CORPORATION: COMPANY OVERVIEW 339 TABLE 478 MCKESSON CORPORATION: PRODUCTS OFFERED 340 TABLE 479 MCKESSON CORPORATION: DEALS, JANUARY 2022–FEBRUARY 2026 341 TABLE 480 ORACLE: COMPANY OVERVIEW 343 TABLE 481 ORACLE: PRODUCTS OFFERED 344 TABLE 482 ORACLE: PRODUCT LAUNCHES, JANUARY 2022–FEBRUARY 2026 345 TABLE 483 ORACLE: DEALS, JANUARY 2022–FEBRUARY 2026 345 TABLE 484 MICROSOFT (NUANCE COMMUNICATIONS, INC.): COMPANY OVERVIEW 347 TABLE 485 MICROSOFT (NUANCE COMMUNICATIONS, INC.): PRODUCTS OFFERED 348 TABLE 486 MICROSOFT (NUANCE COMMUNICATIONS, INC.): PRODUCT LAUNCHES, JANUARY 2022–FEBRUARY 2026 349 TABLE 487 MICROSOFT (NUANCE COMMUNICATIONS, INC.): DEALS, JANUARY 2022–FEBRUARY 2026 349 TABLE 488 TRUBRIDGE: COMPANY OVERVIEW 351 TABLE 489 TRUBRIDGE: PRODUCTS OFFERED 352 TABLE 490 TRUBRIDGE: DEALS, JANUARY 2022–FEBRUARY 2026 353 TABLE 491 HEALTH CATALYST: COMPANY OVERVIEW 355 TABLE 492 HEALTH CATALYST: PRODUCTS OFFERED 356 TABLE 493 HEALTH CATALYST: DEALS, JANUARY 2022–FEBRUARY 2026 357 TABLE 494 VERADIGM LLC: COMPANY OVERVIEW 358 TABLE 495 VERADIGM LLC: PRODUCTS OFFERED 359 TABLE 496 VERADIGM LLC: PRODUCT LAUNCHES, JANUARY 2022–FEBRUARY 2026 360 TABLE 497 VERADIGM LLC: DEALS, JANUARY 2022–FEBRUARY 2026 360 TABLE 498 ATHENAHEALTH: COMPANY OVERVIEW 361 TABLE 499 ATHENAHEALTH: PRODUCTS OFFERED 361 TABLE 500 ATHENAHEALTH: PRODUCT LAUNCHES AND ENHANCEMENTS, JANUARY 2022–FEBRUARY 2026 362 TABLE 501 ATHENAHEALTH: DEALS, JANUARY 2022–FEBRUARY 2026 363 TABLE 502 ATHENAHEALTH: OTHER DEVELOPMENTS, JANUARY 2022–FEBRUARY 2026 363 TABLE 503 GETWELLNETWORK, INC.: COMPANY OVERVIEW 365 TABLE 504 GETWELLNETWORK, INC.: PRODUCTS OFFERED 365 TABLE 505 GETWELLNETWORK, INC.: PRODUCT ENHANCEMENTS, JANUARY 2022–FEBRUARY 2026 366 TABLE 506 GETWELLNETWORK, INC.: DEALS, JANUARY 2022–FEBRUARY 2026 367 TABLE 507 LINCATA, INC.: COMPANY OVERVIEW 368 TABLE 508 LINCATA, INC.: PRODUCTS OFFERED 368 TABLE 509 COGNIZANT: COMPANY OVERVIEW 370 TABLE 510 COGNIZANT: PRODUCTS OFFERED 371 TABLE 511 COGNIZANT: DEALS, JANUARY 2022–FEBRUARY 2026 372 TABLE 512 ONEVIEW HEALTHCARE: COMPANY OVERVIEW 373 TABLE 513 ONEVIEW HEALTHCARE: PRODUCTS OFFERED 374 TABLE 514 ONEVIEW HEALTHCARE: PRODUCT LAUNCHES AND ENHANCEMENTS, JANUARY 2022–FEBRUARY 2026 375 TABLE 515 ONEVIEW HEALTHCARE: DEALS, JANUARY 2022–FEBRUARY 2026 376 TABLE 516 ONEVIEW HEALTHCARE: OTHER DEVELOPMENTS, JANUARY 2022–FEBRUARY 2026 376 TABLE 517 ADVANCEDMD, INC.: COMPANY OVERVIEW 377 TABLE 518 ADVANCEDMD, INC.: PRODUCTS OFFERED 377 TABLE 519 ADVANCEDMD, INC.: PRODUCT ENHANCEMENTS, JANUARY 2022–FEBRUARY 2026 379 TABLE 520 ADVANCEDMD, INC.: DEALS, JANUARY 2022–FEBRUARY 2026 380 TABLE 521 EPIC SYSTEMS CORPORATION: COMPANY OVERVIEW 381 TABLE 522 EPIC SYSTEMS CORPORATION: PRODUCTS OFFERED 381 TABLE 523 EPIC SYSTEMS CORPORATION: PRODUCT ENHANCEMENT, JANUARY 2022–FEBRUARY 2026 382 TABLE 524 EPIC SYSTEMS CORPORATION: DEALS, JANUARY 2022–FEBRUARY 2026 383 TABLE 525 HARRIS HEALTHCARE: COMPANY OVERVIEW 384 TABLE 526 HARRIS HEALTHCARE: PRODUCTS OFFERED 384 TABLE 527 HARRIS HEALTHCARE: DEALS, JANUARY 2022–FEBRUARY 2026 385 TABLE 528 MEDICAL INFORMATION TECHNOLOGY, INC.: COMPANY OVERVIEW 386 TABLE 529 MEDICAL INFORMATION TECHNOLOGY, INC.: PRODUCTS OFFERED 386 TABLE 530 MEDICAL INFORMATION TECHNOLOGY, INC.: DEALS, JANUARY 2022–FEBRUARY 2026 387 TABLE 531 MEDICAL INFORMATION TECHNOLOGY, INC.: OTHER DEVELOPMENTS, JANUARY 2022–FEBRUARY 2026 387 TABLE 532 TEBRA TECHNOLOGIES, INC.: COMPANY OVERVIEW 388 TABLE 533 TEBRA TECHNOLOGIES, INC.: PRODUCTS OFFERED 388 TABLE 534 TEBRA TECHNOLOGIES, INC.: PRODUCT ENHANCEMENTS, JANUARY 2022–FEBRUARY 2026 389 TABLE 535 TEBRA TECHNOLOGIES, INC.: DEALS, JANUARY 2022–FEBRUARY 2026 389 TABLE 536 TELEVOX: COMPANY OVERVIEW 390 TABLE 537 TELEVOX: PRODUCTS OFFERED 390 TABLE 538 TELEVOX: PRODUCT LAUNCHES, JANUARY 2022–FEBRUARY 2026 391 TABLE 539 TELEVOX: DEALS, JANUARY 2022–FEBRUARY 2026 391 TABLE 540 SOLUTIONREACH, INC.: COMPANY OVERVIEW 392 TABLE 541 SOLUTIONREACH, INC.: PRODUCTS OFFERED 392 TABLE 542 SOLUTIONREACH, INC.: PRODUCT LAUNCHES AND ENHANCEMENTS, JANUARY 2022–FEBRUARY 2026 393 TABLE 543 EXPERIAN INFORMATION SOLUTIONS, INC.: COMPANY OVERVIEW 394 TABLE 544 EXPERIAN INFORMATION SOLUTIONS, INC.: PRODUCTS OFFERED 395 TABLE 545 ECLINICALWORKS: COMPANY OVERVIEW 397 TABLE 546 ECLINICALWORKS: PRODUCTS OFFERED 397 TABLE 547 WELLSTACK: COMPANY OVERVIEW 398 TABLE 548 RELATIENT: COMPANY OVERVIEW 399 TABLE 549 LUMA HEALTH INC.: COMPANY OVERVIEW 400 TABLE 550 CIPHERHEALTH INC.: COMPANY OVERVIEW 401 TABLE 551 YOSI HEALTH: COMPANY OVERVIEW 402 TABLE 552 PATIENT ENGAGEMENT SOLUTIONS MARKET: STUDY ASSUMPTIONS 416 TABLE 553 PATIENT ENGAGEMENT SOLUTIONS MARKET: RISK ANALYSIS 417 FIGURE 1 PATIENT ENGAGEMENT SOLUTIONS MARKET SEGMENTATION & REGIONAL SCOPE 42 FIGURE 2 PATIENT ENGAGEMENT SOLUTIONS MARKET: YEARS CONSIDERED 44 FIGURE 3 PATIENT ENGAGEMENT SOLUTIONS MARKET SCENARIO 47 FIGURE 4 GLOBAL PATIENT ENGAGEMENT SOLUTIONS MARKET SIZE, 2024–2031 (USD BILLION) 48 FIGURE 5 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN PATIENT ENGAGEMENT SOLUTIONS MARKET, 2022–2026 48 FIGURE 6 DISRUPTIONS INFLUENCING GROWTH OF PATIENT ENGAGEMENT SOLUTIONS MARKET 49 FIGURE 7 HIGH-GROWTH SEGMENTS IN PATIENT ENGAGEMENT SOLUTIONS MARKET, 2026–2031 50 FIGURE 8 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN PATIENT ENGAGEMENT SOLUTIONS MARKET, IN TERMS OF VALUE, DURING FORECAST PERIOD 51 FIGURE 9 GROWING ADOPTION OF TELEHEALTH AND REMOTE CARE TO DRIVE MARKET 52 FIGURE 10 ON-PREMISES AND US TO ACCOUNT FOR LARGEST NORTH AMERICAN PATIENT ENGAGEMENT SOLUTIONS MARKET SHARE IN 2026 53 FIGURE 11 INDIA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 54 FIGURE 12 PATIENT ENGAGEMENT SOLUTIONS MARKET DYNAMICS 55 FIGURE 13 PORTER’S FIVE FORCES ANALYSIS IN PATIENT ENGAGEMENT SOLUTIONS MARKET 63 FIGURE 14 PATIENT ENGAGEMENT SOLUTIONS MARKET: VALUE CHAIN ANALYSIS 66 FIGURE 15 PATIENT ENGAGEMENT SOLUTIONS MARKET: ECOSYSTEM ANALYSIS 68 FIGURE 16 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS IN PATIENT ENGAGEMENT SOLUTIONS MARKET 75 FIGURE 17 FUNDING (USD MILLION) AND NUMBER OF DEALS IN PATIENT ENGAGEMENT SOLUTIONS MARKET 76 FIGURE 18 PATENT PUBLICATION TRENDS IN PATIENT ENGAGEMENT SOLUTIONS MARKET, 2015–2025 86 FIGURE 19 JURISDICTION AND TOP APPLICANT ANALYSIS FOR PATIENT ENGAGEMENT SOLUTIONS MARKET 87 FIGURE 20 TOP APPLICANTS/OWNERS (COMPANIES/INSTITUTIONS) FOR PATIENT ENGAGEMENT SOLUTIONS MARKET (JANUARY 2015 TO DECEMBER 2025) 88 FIGURE 21 MARKET POTENTIAL OF AI/GEN AI ON PATIENT ENGAGEMENT SOLUTIONS ACROSS INDUSTRIES 91 FIGURE 22 IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS 93 FIGURE 23 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS FOR MAJOR END USERS 106 FIGURE 24 KEY BUYING CRITERIA FOR TOP THREE END USERS 107 FIGURE 25 NORTH AMERICA: PATIENT ENGAGEMENT SOLUTIONS MARKET SNAPSHOT 172 FIGURE 26 ASIA PACIFIC: PATIENT ENGAGEMENT SOLUTIONS MARKET SNAPSHOT 227 FIGURE 27 REVENUE ANALYSIS OF KEY PLAYERS IN PATIENT ENGAGEMENT SOLUTIONS MARKET, 2020–2024 (USD MILLION) 322 FIGURE 28 MARKET SHARE ANALYSIS OF KEY PLAYERS IN PATIENT ENGAGEMENT SOLUTIONS MARKET (2024) 323 FIGURE 29 PATIENT ENGAGEMENT SOLUTIONS MARKET: BRAND COMPARITIVE ANALYSIS 325 FIGURE 30 EV/EBITDA OF KEY VENDORS 326 FIGURE 31 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 326 FIGURE 32 PATIENT ENGAGEMENT SOLUTIONS MARKET: COMPANY EVALUATION MATRIX (2025) 328 FIGURE 33 PATIENT ENGAGEMENT SOLUTIONS MARKET: COMPANY FOOTPRINT 329 FIGURE 34 PATIENT ENGAGEMENT SOLUTIONS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025 334 FIGURE 35 MCKESSON CORPORATION: COMPANY SNAPSHOT 340 FIGURE 36 ORACLE: COMPANY SNAPSHOT 344 FIGURE 37 MICROSOFT (NUANCE COMMUNICATIONS, INC.): COMPANY SNAPSHOT 348 FIGURE 38 TRUBRIDGE: COMPANY SNAPSHOT 352 FIGURE 39 HEALTH CATALYST: COMPANY SNAPSHOT 356 FIGURE 40 VERADIGM LLC: COMPANY SNAPSHOT 359 FIGURE 41 COGNIZANT: COMPANY SNAPSHOT 371 FIGURE 42 ONEVIEW HEALTHCARE: COMPANY SNAPSHOT 374 FIGURE 43 EXPERIAN INFORMATION SOLUTIONS, INC.: COMPANY SNAPSHOT 395 FIGURE 44 PATIENT ENGAGEMENT SOLUTIONS MARKET: RESEARCH DESIGN 403 FIGURE 45 PATIENT ENGAGEMENT SOLUTIONS MARKET: KEY DATA FROM SECONDARY SOURCES 405 FIGURE 46 PATIENT ENGAGEMENT SOLUTIONS MARKET: KEY PRIMARY SOURCES 406 FIGURE 47 PATIENT ENGAGEMENT SOLUTIONS MARKET: KEY DATA FROM PRIMARY SOURCES 407 FIGURE 48 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 407 FIGURE 49 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 409 FIGURE 50 PATIENT ENGAGEMENT SOLUTIONS MARKET: BOTTOM-UP APPROACH 410 FIGURE 51 PATIENT ENGAGEMENT SOLUTIONS MARKET: TOP-DOWN APPROACH 410 FIGURE 52 CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF PATIENT ENGAGEMENT SOLUTIONS MARKET 412 FIGURE 53 PATIENT ENGAGEMENT SOLUTIONS MARKET: CAGR PROJECTIONS (SUPPLY-SIDE ANALYSIS) 412 FIGURE 54 PATIENT ENGAGEMENT SOLUTIONS MARKET: DATA TRIANGULATION METHODOLOGY 415

同分類最新報告（醫療與生命科學）

查看醫療與生命科學全部報告 →

量子訊息有限公司為 MarketsandMarkets 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們